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THEORIES ON THE ORIGIN OF HUMAN CANCER  
Cancer represents a significant burden of disease, as it represents the second leading cause of 
death worldwide. Each year, millions of new cases are expected to occur, with the most 
common sites of tumor onset being lung, colorectal, breast and prostate. 
 
Epidemiologically, it is widely acknowledged that only 5% of human cancers shows strong 
familial aggregation patterns that are compatible with inheritance of high susceptibility alleles 
through the germline, whereas most cancers (95%)  are better described as a “sporadic” 
disease, whose pathogenesis is likely linked to lifestyle-related factors or other environmental 
factors (physical, chemical and biological carcinogens), although genetic susceptibility factors 
are also likely involved. 
 
According to R. A. Willis definition, which dates back to 1960, a tumor "is an abnormal mass of 
tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues and 
persists in the same excessive manner after cessation of the stimuli which evoked the change”. 
[1]. 
 
Nowadays, cancer is the general term used to describe a large group of diseases striking almost 
every human tissue and organ and involving abnormal cell growth endowed with the ability to 
spread beyond their original boundaries and invade other organs outside the site in which they 
arose. 
 
However, despite decades of intensive research have unveiled countless features of cancer, 
from organ to cell and further down to the molecular level, the processes underlying cancer 
initiation and progression are still a matter of intense debate. Indeed, a number of theories 
have been put forward to try to explain how cancer arises.  
In broad terms, the most acknowledged models could be gathered into a simpler scheme of 
two types: (i) according to the first model, successive waves of genetic changes in a target cell 




changes in tumor microenvironment along with changes in target cell population are necessary 
for cancer development [2]. 
Solid tumors generally contain a parenchyma of proliferating neoplastic cells and a 
supporting tissue, or stroma. Since the tumor size typically increases with time, it has long been 
hypothesized that the underlying cause of tumor formation must have been excessive cell 
proliferation in the parenchyma. Therefore, for many years cancer has been mainly interpreted 
as a cell-based disease, as described by the somatic mutation theory (SMT), first enunciated in 
1914 by Theodor Boveri and still prevailing in the cancer research community.  
The SMT is based on the following premises: 1) cancer is derived from a single somatic cell 
that progressively accumulates multiple genetic (and epigenetic) alterations, whence the 
monoclonality concept; 2) these mutations occur in genes that control cell proliferation, cell 
death or DNA damage repair and 3) as implicitly inferred, the default state of cell proliferation 
in multicellular organisms is quiescence [3]. 
This theory gained a progressively increasing credibility when many experimental 
evidences led to the discovery of oncogenes and tumor suppressor genes over the last three 
decades. Indeed, cancer cells are well known to bear countless mutations in genes that are 
physiologically involved in regulating cell proliferation and cell death, and these mutations are 
considered the leading cause for the wide range of human cancers that affect millions of people 
worldwide. The “normal” alleles of these genes came to be called proto-oncogenes, to 
emphasize their intrinsic tumorigenic potential, while the mutated, cancer-causing forms were 
accordingly called oncogenes. Since oncogenes actively promote cell proliferation, mutations 
converting proto-oncogenes to oncogenes typically increase or deregulates the activity of the 
encoded protein or, alternatively, raise the expression of the normal gene to unphysiological 
levels. Such mutations have therefore been given the attribute of “gain-of-function mutations”, 
by which only one copy of these genes needs to be mutated in order to promote cancer [4]. 
On the other hand, tumor suppressor genes (TSGs) encode for proteins that physiologically 
inhibit cell proliferation, or act as “brakes” for the cell cycle by regulating apoptotic signals.  
Since they normally inhibit the formation of tumors, mutations in these genes contribute to the 




this second class of tumor-related genes are thus typically “loss-of-function” mutations and 
must usually affect both copies of the gene in order to drive cancer development [4]. 
Given these premises, the SMT’s view of tumorigenesis entails a process analogous to a 
Darwinian process, in which accumulating genetic alterations lead to progressive acquisition of 
novel capabilities that enable the tumor cells to growth increasingly fast, evade cell death and 
finally proceed to metastatic dissemination. In 2000, Hanahan and Weinberg, two strong 
exponents of the SMT theory, proposed that for a full-blown cancer to arise, cancer cells have 
to acquire the following six essential capabilities that are now widely known as the “hallmarks 
of cancer”:  
1) self-sufficiency in growth signals 
2)  insensitivity to antigrowth signals 
3)  resistance to cell death 
4)  limitless replicative potential, 
5)  sustained angiogenesis 
6)  tissue invasion and metastasis [5]. 
 
Later on, growing experimental evidences reported the occurrence of a significant cross-talk 
between the cancer cells and the surrounding stroma, supporting the hypothesis that the 
tumor microenvironment plays an essential role in cancer development and progression as 
well. Accordingly, in 2011 Hanahan and Weinberg updated their theory by further adding two 
novel cancer hallmarks: reprogramming of energy metabolism and escaping immune 
destruction [6]. 
In the last decade, an independent theory for cancer development has been proposed 
under the name of tissue organization field theory (TOFT) [3]. When compared to the SMT, this 
theory is based on drastically different premises: 1) carcinogenesis is a problem of tissue rather 
than cell organization and is therefore somehow attributable to a defect in organogenesis 
(whence the “development gone awry” concept) and 2) proliferation rather than quiescence is 




Of note, a dysfunctional interaction between the stromal and parenchymal compartment 
lies at the core of the TOFT: a single or multiple carcinogenic exposure acts by altering the 
reciprocal biochemical, biophysical and biomechanical communication network between the 
epithelial cells that will give rise to most cancers and the surrounding stromal cells. As a 
consequence, the proliferation and motility restraints imposed by the normal tissue 
architecture on the relevant tissue are lost, and hyperplasia/displasia occur.  
This model largely relies on the presence and the key role of a wide range of stromal cell 
types in the tumor surroundings, such as cancer-associated fibroblasts (CAFs), endothelial cells, 
pericytes, tumor-associated macrophages (TAMs) and progenitor cells of the tumor stroma. 
According to the TOFT, all these cell types could display either a cancer-promoting or -inhibitory 
activity. For instance, altered epithelial cells may trigger stromal reactions that in turn confer 
reciprocal signal exchanges in tumor epithelia to promote further carcinogenic processes. 
Ultimately, such aberrant reciprocal tumor–stroma interaction culminates in increased 
migratory, invasive, and metastatic behavior of cancer cells. 
Hence, under the TOFT paradigm carcinogenesis and tumor progression are thought of not just 
as cell-autonomous, cancer cell-centered processes, but rather as a complex phenomenon 
involving heterotypic multicellular interactions within the newly formed cancer tissue.  
Under such view, cancer is therefore basically equated to an ecological/community system 
whose participants are exchanging wrong information among them. 
 
However, both cancer theories had to be somehow integrated with recent experimental 
data based on the increased understanding of stem cell biology, which reported several 
similarities between cancer cells and normal stem cells, thus leading to the notion that cancer 
may arise from the accumulation of mutations within normal, tissue-resident stem cells. This 
subset of cells, termed cancer stem cells (CSCs), were identified within several cancer types and 
appears to selectively possess tumor-initiating properties and to be inherently drug resistant 
and are hence predicted to contribute to both cancer development and relapse. These findings 
ultimately led to postulate a variant SMT model, the cancer stem cell (CSC) theory, which can 




heterogeneity [7]. However, the contribution of the stromal compartment to tumor growth and 
development is nowadays a widely accepted notion in the cancer research community and, in 




THE ROLE OF THE HUMAN RNASET2 IN CANCER 
 
 Irrespective of the origin of cancer, almost all human tumors show consistent 
chromosomal aberrations and genomic instability is actually considered a typical feature for 
many human cancers [8]. Indeed, almost all solid tumors and several hematological 
malignancies display various degrees of karyotype changes, including chromosome 
translocations, deletions and duplications as well as more subtle aberrations such as small-scale 
rearrangements, deletions and amplifications. Of note, the functional relevance of these 
chromosomal rearrangements in the tumorigenic process has long been acknowledged, since a 
wide range of allelic analyses on tissue cancer samples have reported frequent loss-of-
heterozygosity (LOH) events on specific chromosomal regions, supporting the hypothesis of the 
presence of tumor-suppressor genes (TSGs) or other genes related to tumor pathogenesis in 
the regions underlying LOH [9]. 
In this context, human chromosome 6 has been intensely investigated to find putative 
TSGs, since several studies have consistently reported the occurrence of chromosomal 
anomalies, mostly in the peritelomeric region of this chromosome [10]. Indeed, in a wide range 
of solid and hematological neoplasia (carcinomas of the ovary, breast, uterus, melanoma, non-
Hodgkin B-cell lymphoma and acute lymphoblastic leukemia) rearrangements and deletions in 
this chromosomal region have been found. By focusing on this chromosome, our research 
group has mapped, cloned and characterized the RNASET2 gene (the only human member of 





Ribonucleases (RNases) represent an important class of enzymes found in almost all 
organism which participate in many cellular functions, from DNA replication to control of gene 
expression and defense against microorganisms [11]. In recent years, enzymes and other 
proteins affecting RNA fate and turnover are becoming increasingly important to better 
understand the basic processes underlying cell proliferation, differentiation, apoptosis, and 
their alterations with putative implications in cancer development.  
RNases can hydrolyze single-stranded RNA, double-stranded RNA, and RNA-DNA hybrid 
molecules [12]. Among those that hydrolyze single-stranded RNA are the transferase-type 
RNase. This set of RNases are secreted or localized inside cellular structures associated with the 
secretory pathway, but normally not associated with the presence of RNA. They have been 
ranked in several ways on the basis of their base specificity, structure, function, optimal pH, and 
origin but, in broad terms, they are currently classified as alkaline RNases (RNase T1 family and 
RNase A family) and acid RNases (RNase T2 family) [12]. 
T2 ribonucleases were first classified by their similarity to the first acid RNase purified 
from Aspergillus oryzae [13] and, unlike members of the A and T1 family, are widely distributed 
among taxa (viral surface proteins, bacteria, fungi, plants and higher animals). All members of 
the T2 family show a defined feature in their primary structure, represented by two 
characteristic motifs called CAS I and II (conserved active-site segments), endowed with the 
catalytic function of these enzymes. Of note, a key feature of Rh/T2/S ribonuclease family 
members is their highly disparate physiological functions, their extreme evolutionary 
conservation and their subcellular localization, which also varies and includes compartments 
where RNA is not expected to be readily available, suggesting that these enzymes could have 
other roles that might be independent from their catalytic activities [12]. 
As mentioned above, the only human member of the T2 family is called RNASET2 and is 
present in the human genome on chromosomal region 6q27 as a single copy gene, organized 
into nine exons and eight introns. Human RNASET2 is a 256-residues long protein with a 
predicted molecular weight of 30 kDa. The protein is composed of a signal peptide for 
secretion at the N-terminal, two CAS I/II catalytic sites and three putative N-glycosylation sites, 





Figure 1: Schematic representation of the human RNASET2 protein 
The human RNASET2 protein is composed by 256 aminoacids. Blue box: signal peptide for secretion; 
Gray boxes: Conserved Active Sites (CAS I-II); Blank boxes: N-glycosilation sites. 
 
Within the cell, RNASET2 is present in three forms of different molecular weight, namely 
36, 31 and 27 kDa. The 36 kDa isoform represents the full-length and secreted form, whereas 
the other two isoforms represent intracellular forms derived from proteolytic cleavage 
occurring at the C-terminal end. A subcellular fractionation assay on RNASET2-overexpressing 
Hey4 ovarian cancer cell line suggested that RNASET2 is produced as the full-length form, which 
is detected in the secretory pathway, whereas the proteolytic cleavage forms are likely 
originated during transport/delivery to intracellular Processing Bodies (PBs) and lysosomes. All 
three forms are similarly glycosylated [14]. 
Due to the chromosomal location of the human RNASET2 gene in a region frequently 
rearranged in tumors, the putative tumor suppressive role of this gene has long been 
investigated by our research group. 
Using ovarian carcinoma as an experimental model, the RNASET2 gene has been first ascribed 
to the class II tumor suppressor genes family, since its structure was reported to be structurally 
intact, but frequently hypoexpressed or silenced in cancer tissues [15]. 
To better define the role of RNASET2 as a tumor suppressor, both ovarian carcinoma (the 
human Hey3Met2 cell line) and malignant melanoma (the human SK-MEL 28 cell line) were 
used as experimental models. Strikingly, in vivo xenograft assays carried out in nude mice with 
RNASET2-overexpressing clones derived from both cell lines showed a marked RNASET2-
mediated suppression of tumorigenic and metastatic potential in vivo [16,17]. 
 
Additionally, the analysis of Hey3Met2 human ovarian cancer cells overexpressing a 


















CAS sites were replaced by phenylalanine residues) showed that RNASET2-mediated tumor 
suppression is carried out independently from its ribonuclease activity (see Figure 2).  
 
Figure 2: Image from Acquati F. Microenvironmental control of malignancy exerted by RNASET2, a 
widely conserved extracellular RNase. Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1104-9. 
Expression of RNASET2 in the human Hey3Met2 cell line is able to suppress tumor growth in vivo 
following inoculation of nude mice with these clones. The expression of a catalytically inactive RNASET2 
protein still suppresses the tumorigenic potential.    
 
Moreover, a close histological examination of xenograft tumors sections showed that the 
tumor suppressive role carried out by the RNASET2 gene was associated with a consistent 
infiltrate of host cells belonging to the M1 subclass of macrophages, which is known to have 
antitumorigenic properties.  
Indeed, macrophages regulate numerous functions related to tissue remodeling, 
homeostasis, inflammation and disease. These pleiotropic features of macrophages appear to 
be related to their high plasticity, since a wide range of functional states have been described 
for this cell type, with the well-known M1- and M2-polarized populations representing the two 
extremes of this range. Of note, M1-polarized macrophages are known to actively contrast 
tumor growth by secreting several inflammatory cytokines, whereas M2-polarized 
macrophages (also known as Tumor-Associated Macrophages or TAMs) are endowed with pro-
tumoral activities [18]. 
 
To further define the role of host macrophages in RNASET2-mediated tumor suppression, a 




lack both lymphocytes and NK cells, was exploited to evaluate if the population of host-derived 
cells infiltrating RNASET2-expressing tumors could be functionally responsible for RNASET2-
mediated suppression of tumorigenicity. Indeed, when mice were pretreated with the 
macrophage-depleting agent clodronate before inoculation of RNASET2-expressing Hey3Met2 
cells, the tumor suppressing activity of wild-type RNASET2 turned out to be largely impaired 
(Figure 3) [19]. 
 
Figure 3: Image from Acquati F. Microenvironmental control of malignancy exerted by RNASET2, a 
widely conserved extracellular RNase. Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1104-9. 
Rag/ -chain mice were used to further analyze the functional role of host macrophages in the RNASET2-
mediated tumor suppression. Mice either mock-treated or treated with clodronate (a macrophage-
depleting agent) before inoculation with RNASET2-expressing Hey3Met2 clones were compared. 
Representative images of animals are presented with tumor growth kinetics that show clear increase in 
tumorigenicity for treated mice. 
 
These results are in keeping with an extensive body of evidence from the literature, 
which strongly suggests a role for T2 RNases in the modulation of innate immune response. As 
an example, the T2 ribonuclease omega-1 secreted from Schistosoma mansoni eggs has been 
found to be the major soluble factor involved in priming dendritic cells to promote Th2 
lymphocyte differentiation [20]. Moreover, preliminary results on the invertebrate 




cell macrophages induced by RNASET2 injection in the body wall (Baranzini et al, manuscript in 
preparation). 
The antineoplastic features of RNASET2 were also confirmed by a complementary in vivo 
experimental model established in our lab. RNASET2 was knocked-down by RNA interference in 
the OVCAR3 human ovarian cancer cell line, which shows high endogenous levels of this 
protein. In agreement with the data previously obtained with the Hey3Met2 cell line, silencing 
of RNASET2 expression in OVCAR3 cells caused an increased in cancer growth rate in vivo, 
coupled with a significant decrease of M1-polarized macrophage infiltration as a distinct 
feature of the RNASET2-silenced tumors [21]. 
Noteworthy, we also demonstrated that the RNASET2 protein behaves as a strong in vitro 
chemoattractant for human monocytes and it can bind the monocyte-macrophage cell surface 
in a dose-dependent manner, which suggested the occurrence of a receptor-mediated 
interaction [21]. 
Taken together, these data strongly suggest that the tumor microenvironment (in particular the 
monocyte-macrophage cell population) seems to play a crucial role in RNASET2-mediated 
tumor suppression in vivo. Within this frame, we defined RNASET2 as a gene endowed with a 
marked non-cell-autonomous oncosuppressive role.  
 
However, in light of the very disparate functional roles that have been attributed to 
members of the T2 RNase family [22], the occurrence of an independent cell-autonomous role 
for RNASET2 cannot be formally ruled out. Therefore, based on both the extreme conservation 
of T2 ribonucleases throughout most phyla and the presence of an intracellular pool of 
RNASET2, we hypothesized that, besides its previously reported role in microenvironmental-
mediated tumor suppression, RNASET2 could be endowed with an ancestral cell-autonomous 
activity that might be related to cancer suppression as well. 
In particular, drawing from the evidences that several members of the T2-Rnase family 
appear to be activated upon stress conditions [23] and that the RNASET2 protein re-localize to 
processing bodies (PBs) in conditions of metabolic stress, we started to investigate whether 




challenging ovarian cancer cell lines with different stress-inducing chemicals or treatments, a 
significantly increase of RNASET2 protein levels, in both intra- and extracellular compartments, 
was observed in response to most applied stresses [24]. 
Of note, several cancer-related parameters were found to be affected in vitro in RNASET2-
silenced OVCAR3-cells, supporting the occurrence of a cell-autonomous oncosuppressive role 
for this gene. 
Moreover, a marked RNASET2-mediated remodeling of the actin cytoskeletal organization 
was observed as well, a feature which is clearly related to cancer due to its implications in cell 
motility and adhesion [24]. 
Again, the observed cytoskeleton-remodeling ability of a tumor suppressing T2 
ribonuclease is in keeping with previous works, since a strong antitumor activity has been 
described for a fungal member of T2 family ribonucleases, named ACTIBIND due to its ability to 
bind actin [25]. 
 
Taken together, these data prompted us to consider RNASET2 as a protein endowed with a 
marked pleiotropy, which refers to the phenomenon by which a single gene can affect multiple 
biological processes and, by consequence, several traits [26]. 
Particularly, we ascribe RNASET2 to the growing family of “moonlighting proteins”, which 
describes a class of multifunctional proteins that are involved in several complex biological 
processes such as DNA replication, transcription and tumor suppression, but that were 
previously identified for totally unrelated functions. Of note, a typical feature of these proteins 
is that their function can vary widely as a consequence of their cellular localization and cellular 
context and this seems to be a feature belonging to RNASET2 as well [27,28]. 
 
In the light of these findings, it is therefore of great interest to carry out further investigations 
in order to shed more light on RNASET2’s modes of action in the context of cancer suppression. 
To this end, an interesting goal would be to develop new experimental models to better 




innate immune system operates in vivo. To this aim, an in vitro cellular model to investigate 
how RNASET2 affects the macrophage polarization pattern could be highly informative. 
 
Moreover, the oncosuppressive role of RNASET2 in the context of a competent immune system 
would be worth investigating in a proper in vivo experimental model as well. This task could be 
best achieved by developing a syngeneic mouse model where RNASET2 expression is 
experimentally modulated. 
Finally, it would be extremely important to confirm (and possibly extend) the role(s) of 
RNASET2 in other cellular models representing cell types known to be susceptible to cancer 
development following rearrangements of the 6q27 chromosomal region, such as the 
mammary epithelium [29]. In this context, the MCF7 breast cancer cell line represents a widely 
used experimental model, derived from a pleural effusion taken from a patient with metastatic 
breast cancer [30]. This cell line has been thoroughly used for in vitro breast cancer studies 
since it has retained several features that are peculiar to the mammary epithelium. Moreover, 
these cells might be exploited to compare in a single experimental model the effect of RNASET2 
in the context of two independent experimental settings (2D and 3D cell culture). 
Indeed, it is widely acknowledged that a fully formed organ is significantly more 
complex than cells kept in culture monolayers. 3D cultures are beginning to bridge the gap 
between these two experimental models, by retaining some of the architectural features that 
are usually lost when the structure of organs and tissues is destroyed by dissociating cells and 
culturing them in 2D. Of note, 3D models are known to faithfully recreate some key aspects of 
the tissue microenvironment and, in some cases, to provide a more comprehensive and 
relevant biological information that is very difficult (if not impossible) to recapitulate from 2D 
models [31]. 
As a matter of necessity, 3D models of the mammary gland acinus have been developed 
for almost 30 years. Under proper culture conditions, mammary epithelial cells form polarized 
spheroid structures (also called acini) which consist of a central lumen, a single layer of 
polarized luminal epithelial cells surrounded by myoepithelial cells and a basement membrane. 




epithelial cell transformation, since in the early stages of breast cancer development an 
increased proliferation rate of mammary epithelial cells is coupled to a loss of acinar 
organization. This is the reason why three-dimensional culture conditions are increasingly being 
used to address the molecular mechanisms by which oncogenes or tumor suppressor genes 
could influence mammary epithelial cell transformation [32]. 
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The RNASET2 gene maps to human chromosome 6q27, a region that has been 
consistently found rearranged in many solid and hematological tumors. This gene encodes for 
the only human secreted acid ribonuclease of the T2 family.  
Our previous experimental data proved a role in the control of tumorigenesis carried 
out in vivo by this gene in two independent human ovarian cancer cell models. Moreover, 
RNASET2-mediated tumor suppression in vivo turned out to involve the recruitment into the 
tumor mass and possibly activation of innate immune cells belonging to the 
monocyte/macrophage lineage. Indeed, a preliminary in vivo functional characterization 
showed that RNASET2 specifically recruits M1 macrophages, which are known to carry out a 
cancer antagonizing role. These data allowed us to hypothesize a non-cell autonomous 
oncosuppressive role for extracellular RNASET2. [16,19,21]  
In recent investigations, RNASET2 was also shown to behave as a stress response gene, 
since cells cultured under a wide range of stress condition showed a trend for an increase of 
RNASET2 expression and secretion. Specifically, by challenging three independent ovarian 
cancer cell lines with hypoxic conditions, which represent a general hallmark of many cancer 
tissues, a clear increase in RNASET2 expression and secretion was observed, thus supporting 
the notion of a non cell-autonomous role for RNASET2 reminiscent of that related to 
“alarmins”, a wide family of extracellular danger-signaling molecules involved in stress response 
at the tissue level [24]. 
Finally, a cell-autonomous role in tumor suppression has been reported for the RNASET2 
gene as well, likely involving its ability to affect the cell cytoskeleton [20,24]. 
 
Given these premises, which strongly suggest a highly pleiotropic oncosuppressor role 
for RNASET2, we decided to further characterize this gene from a functional point of view. 
 
Within this conceptual frame, in the attempt to gain more insights into the functional 
interaction between this protein and cells from the monocyte/macrophages lineage, the first 
aim of my work was to analyze the effect of RNASET2 protein in the recruitment and 
polarization pattern of macrophages in both in vitro and in vivo systems. 
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The human monocyte-like THP-1 cell line was used to investigate whether RNASET2 
could affect the macrophage polarization pattern. Known M1/M2 markers were analyzed by 
qPCR following experimental differentiation and polarization of the THP-1 parental cell line, 
which shows high endogenous RNASET2 levels, and at the same time we analyzed the same cell 
line devoid of the RNASET2 gene through silencing [33]. Moreover, to verify the evolutionary 
conservation of the role of RNASET2 in innate immune system regulation, its ability to recruit 
and possibly activate macrophages was investigated using the medicinal leech as an 
experimental model. 
 
Furthermore, since our previous in vivo data on RNASET2-mediated tumor suppression 
were obtained in nude mice, a second aim of my PhD project was to investigate the 
oncosuppressive role of this gene in a syngeneic mouse model. This could provide a more 
detailed knowledge about the interplay of RNASET2 with the tumor microenvironment in a 
completely immunocompetent in vivo experimental model instead of an immunosuppressed 
one. Additionally, a syngeneic model could also rule out any possible immunological influence 
of the human protein on the mouse immunological set up that might have arisen using 
xenograft-based in vivo assays. 
To this end, we analyzed the expression of the murine ortholog of RNASET2 in different 
mouse cancer cell lines and chose the C51 and TSA cell lines (representing colon and mammary 
mouse cancer cells, respectively) to overexpress the murine RNASET2 protein and evaluate how 
such overexpression affected several cancer-related parameters in vitro and in vivo. 
 
As mentioned before, chromosomal anomalies of the long arm of chromosome 6 have 
long been reported for several cancer types, including breast cancer. Therefore, the third task 
of my work has been to further address the oncosuppressive role of RNASET2 in the context of 
mammary carcinogenesis. In particular, in line with a recent view of cancer development and 
progression as a process involving an altered tissue organization pattern (by which cancer 
would represent a disease of “development gone awry”), we decided to investigate the 
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pleiotropic roles of RNASET2 as a tumor suppressor gene in the context of breast 
morphogenesis.  
To this end, the human MCF7 breast cancer cell line was chosen as an experimental 
model.  
 
Furthermore, recent data gathered in collaboration with another research group 
showed that, when four different cell populations of healthy mammary gland (namely luminal 
terminally differentiated cells, myoepithelial basal-like cells, stem cells and EMT cells) were 
sorted by cytofluorimetry, a striking gradient of RNASET2 expression was observed, with more 
differentiated cells from the luminal population showing the highest expression level whereas 
other cell populations showed a progressively decreasing expression, which reached a minimal 
value in the stem cells population.  
On the basis of these data, we silenced the expression of RNASET2 in the luminal breast 
cells population to analyze putative changes in their ability to form differentiated organoid 
structures in 3D. Organoids represent an important bridge between traditional 2D cultures and 
in vivo models, as they are more physiologically relevant than monolayer culture models, so this 
culture system is expected to provide a more reliable experimental model to investigate the 

































Adhesion growth: Hey3Met2 (human ovarian cancer). Culture medium: DMEM-F12 + 10% FBS + 
1% L-glutamine.  
MCF7 (human breast cancer). Culture medium: RPMI, 10% FBS, 1% L-Gln,10 μg/ml insulin. 
C51 (mouse colon cancer) and TS/A (mouse mammary cancer). Culture medium: DMEM + 10% 
FBS + 1% L-glutamine.  
Stably-transfected cell clones  
Culture medium: basic medium + selective antibiotic. MCF7: 600 μg/ml G418; C51: 400 μg/ml 
G418; TS/A: 300 μg/ml G418. 
Suspension growth: THP-1 (human acute monocytic leukemia). Culture medium: RPMI-1640 + 
10% heat-inactivated FBS + 1% L-glutamine.  
RNASET2 Knockdown in THP-1 Cells 
The recombinant pSicoR expressing vector bearing a RNASET2-targeting shRNA [21] was stably 
transfected into THP-1 cells with the Cell Line Nucleofector Kit V (Amaxa). The efficiency of 
RNASET2 knockdown was evaluated by Western blot analysis before every experiment. Cells 
were maintained under selection (0.75 μg/ml puromycin) throughout all the experiments to 
ensure the stability of the pool. 
Culture conditions: 37°C, 5% CO2, humidified atmosphere.  
All cell lines are routinely screened for the absence of mycoplasma contaminations by 
performing a nested PCR. 
Differentiation and polarization protocol of THP-1 cells 
THP-1 cells were differentiated into M0 macrophages by addition of 5 ng/ml Phorbol 12-
myristate 13-acetate (PMA) for 48 hours in MT6 wells at a concentration of 0.7x106 cells/ml. 
Following monocyte differentiation into macrophages for 48 h, the medium was changed after 
three washes and macrophages were polarized into either M1 or M2 as follows: M1 
polarization was achieved by treatment with 100 ng/ml LPS (from Salmonella abortus equi S-
form – EnzoLifeSciences) and 20 ng/ml IFN-γ (Bio Basic – RC217-17), whereas M2 polarization 
was induced by treatment with 20 ng/mL IL-4 (Peprotech – 200-04). 
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THP-1-derived macrophages were allowed to polarize for 18 h (M1) or 48 h (M2). Three 
different M1 polarization regimens were used: 20 ng/mL IFN-  alone, 100 ng/ml LPS alone or a 
combination of the two (IFN-γ+LPS), and a single for M2 polarization: 20 ng/mL IL-4 treatment. 
A non-induced macrophage control population, cultured without polarizing cytokines, was used 
as control and referred to as M0. Endotoxin-free recombinant RNASET2 protein was used at a 
0.22 M concentration. Control macrophages were treated with the same endotoxin-free 
vehicle (PBS) used for recombinant RNASET2 storage. [33] 
The recombinant protein was produced in the yeast Pichia pastoris expression system and 
purified as previously reported [34].  
Transfection 
For transfection experiments, cells were plated in 6-well plates the day before experiment and 
were incubated overnight at 37°C (in a humidified 5% CO2 incubator) to reach 80% confluence 
the day of transfection, which was performed with Lipofectamine 2000 according to the 
manufacturer’s protocol. 
 
IN VITRO ASSAYS 
Cell proliferation assay 
The CellTiter® 96 Non-Radioactive kit (Promega) was used to determine viable cell number 
based on the cellular conversion of a tetrazolium salt into a formazan product. The absorbance 
of the solubilized formazan product (directly proportional to the number of cells) was recorded 
using a 96-well plate reader daily over a 7 or 10-days period. Samples were seeded in 
triplicates. 
Colony-formation assay 
50, 100 or 150 cells/well were plated in six-wells culture plates. Following a 14 days incubation, 
clones were stained with 1% methylene blue/50% ethanol and manually counted. 
Apoptosis assays 
Cells were plated in 6-well plates the day before experiment and were incubated overnight at 
37°C (in a humidified 5% CO2 incubator). The day of the experiment they were challenged with 
either 100 nM Cisplatin or 200 μM CoCl2. Treatments were conducted in technical triplicates. 
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24-hours after the treatment, 5x105 cells were fixed in 0.5 ml of ice-cold 100% ethanol, 
centrifuged, washed with PBS, resuspended in the dying solution (50 μg/ml Propidium Iodide, 
20 μg/ml RNase in 1X PBS) and analyzed with FACSCalibur flow cytometer. 
Mammosphere assay 
For mammosphere formation, cells were enzymatically and mechanically detached and 
dissociated and 1,000 cells/well (96-wells plates) or 25,000 cells/well (6-wells plates) were 
seeded into ultralow attachment plates and cultured for 1 or 2 weeks in their grown medium 
supplemented with 1x B27 and 0.75% methylcellulose (viscosity 4,000 cP). Cell cultures were 
maintained in a humidified 5% CO2 incubator. 
 
GENE EXPRESSION ANALYSIS 
Total RNA was extracted from cells using RNeasy Plus Mini Kit (Qiagen) and reverse transcribed 
into complementary DNA (cDNA) with random primers according to the instructions of the High 
Capacity cDNA Reverse Transcription Kits (Applied Bioystems). Quantitative PCR, using gene-
specific primers, was performed on CFX Connect (Biorad) with the Power SYBR-green PCR 
Master Mix (Applied Biosystems), following the manufacturer's instructions. Amplification 
reactions were performed in triplicate. Results were normalized using the house-keeping gene 
GAPDH and the cyclethreshold method and are expressed as relative fold over the control 
group. 
List of primers used for the three different projects: 
Primer name Forward (5'-3') Reverse (5'-3') 
β-actin CCAAGGCCAACCGCGAGAAGATGAC AGGGTACATGGTGGTGCCGCCAGAC 
EPCAM AGGAAGAATGTGTCTGTGAAAACTACA TGAAGTACACTGGCATTGACGAT 
Beta-casein GCCACTTGCCCCAGTTCAT ACAAAGACGGAAAAGGCATCA 
CD44 CAGACCTGCCCAATGCCTTTGATG CTTTCTGGACATAGCGGGTGCC 
CD24 TGCTGCTGCTGGCACTGCTCCTA CAGAGTTGGAAGTACTCTGGGAGG 
ALDH1A1 TCCTTGGAAATCCTCTGACCCCAG GGCCCCTTCTTTCTTCCCACTC 
3xFLAG for qPCR AAAGACCATGACGGTGATTATAAAG ACTTGTCATCGTCATCCTTGTA 
CXCL10 GACATATTCTGAGCCTACAGCA CAGTTCTAGAGAGAGGTACTCCT 
TNF TGCACTTTGGAGTGATCGG TCAGCTTGAGGGTTTGCTAC 
CCL22 CTCCAACCTCCAATACCCA CATAGCATGAATTTGATTGTCAGC 
MRC1  GGTTTTGGAGTAATATTCACTGTTCT TCCATCTTCCTTGTGTCAGC 
GAPDH CTCTCTGCTCCTCCTGTTC GCGCCCAATACGACCAA 
CCL17 GCCATCGTTTTTGTAACTGTGC CAAGACCTCTCAAGGCTTTGC 
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WESTERN BLOT ANALYSIS 
Adherent cells were mechanically scraped in PBS + 5mM EDTA and resuspended in lysis buffer 
(0.5% Igepal, 0.5% Triton X-100 in PBS + 5mM EDTA) supplemented with protease inhibitors 
cocktail (PMSF, benzamidine, aprotinin, and leupeptin). Suspended cells were collected, 
washed and resuspended in lysis buffer. Quantification of total proteins was performed with 
Bradford reagent (BIORAD), using bovine serum albumin as standard. For the SDS-PAGE 
analysis, 30-70 μg of intracellular lysate were loaded. Immunoblot analysis was performed 
using standard procedures and detected with a chemiluminescent substrate (WESTAR ETA C 
ULTRA 2.0, Cyanagen). 
Antibodies: Polyclonal rabbit anti-RNASET2 (Davids Biotechnologie GmbH, Regensburg, 
Germany); monoclonal rabbit anti-FLAG (SIGMA ALDRICH); HRP anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories, West Grove, USA); mouse monoclonal anti- -tubulin (SIGMA 
ALDRICH); HRP anti-mouse IgG (ABNOVA). 
 
ACTIN CYTOSKELETON STAINING 
Cells were grown on coverslips for 24 hours and then processed for immunostaining. Cells were 
fixed in 3% paraformaldehyde and then permeabilized using Triton X-100. Phalloidin-TRITC dye 
(SIGMA) incubation was performed in diluted blocking solution (3% BSA in PBS). Coverslips 
were mounted on microscope slides using Vectashield mounting medium (Vector). 
Fluorescence/confocal microscopy images were acquired. 
 
CLONING OF THE HUMAN RNASET2 CODING SEQUENCE IN THE INDUCIBLE EXPRESSION 
VECTOR 
The inducible expression vector bearing the mouse Rnaset2 cDNA was bought from the 











Figure 4. Inducible vector map with the cDNA for mRnaset2 or hRNASET2 
 
In order to have a control for comparison of transfection and expression efficiency, we decided 
to clone the wild-type human RNASET2 coding sequence inside the same plasmid.  
A construct already available in our lab was used as a template for a PCR reaction with the 
following primer pair:   
44-SalI Fw  




The amplification product was digested with SalI, gel purified and cloned into the vector builder 
plasmid, devoid of the mouse gene, before transforming in the DH5α E. coli strain. Plasmid DNA 
was purified and then sent to sequencing (BMR, Padova, Italy), before using it. 
 
CLONING OF THE DIFFERENT FULL OR CHIMERICH CDNA IN THE PCDNA3 PLASMID FOR THE 
SWAP APPROACH 
The pcDNA3 plasmid was chosen as backbone. The inducible vector bought from the 
VectorBuilder company was used as a template for a PCR reaction with the following primer 
pair for inserting the 3xFLAG sequence into the pcDNA3 vector: 
3xFLAG_version2 Rev: 5’ AGAGGTTCTAGACTACTTGTCATCGTCATCCTTGTAATC 3’ 
3xFLAG_version2 Fw: 5’ AACTGGCTCGAGGACTACAAAGACCATGACGGTGA 3’ 
or hRNASET2
Or 9635 bp
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The amplification product was digested with XhoI and XbaI, gel purified and cloned into the 
pcDNA3 vector before transforming in the DH5α E. coli strain. Plasmid DNA was purified and 
then sent to sequencing (BMR, Padova, Italy), before using it for the following steps. 
Different constructs, already available in our lab, bearing the human and mouse RNASET2 gene 
were used as templates for PCR reactions with the following primer: 
hRNASET2 Fw: 5’ ACCTTGGGATCCACCATGCGCC 3’ 
hRNASET2 Rev: 5’ ACCTGAGAATTCATGCTTGGTCTTTTTAGGTGGG 3’ 
mRNASET2A Fw: 5’ TGCTAAGGATCCACCATGGCGCCG 3’ 
mRNASET2A Rev: 5’ ACCTGAGAATTCATGTTGGGTCTTTGTAGGTGGA 3’ 
mRNASET2A truncated Rev: 5’ ACCTGAGAATTCCTGCTCCCCTGGCTCA 3’ 
hRNASET2 overlap Fw: 5’ TGAGCCAGGGGAGCAGCCGTCCCCCAAGCAG 3’ 
hRNASET2 overlap Rev: 5’ TTCCTGCCTGGAGGACAGCTGCTCCCCCGGCT 3’ 
mRNASET2A overlap Fw: 5’ AGCCGGGGGAGCAGCTGTCCTCCAGGCAGGAA 3’ 
mRNASET2A overlap Rev: 5’ CTGCTTGGGGGACGGCTGCTCCCCTGGCTCA 3’ 
The amplification products were digested with EcoRI and BamHI, gel purified and cloned into 
the pcDNA3 vector (together with a synthetic oligo coding for a TEV protease recognition site 
with EcoRI and XhoI sticky ends) before transforming in the DH5α E. coli strain. Plasmid DNA 
was purified and then sent to sequencing (BMR, Padova, Italy), before using it for the 
transfections. 
A schematic representation of the pcDNA3 vector and all cDNAs cloned is shown in figure 5. 
Figure 5. pcDNA3 plasmid 
vector and schematic 
representation of cloned 
cDNAs 
The pcDNA3 (Invitrogen) 
was used as backbone. Full-
length isoforms of humand 
and mouse RNASET2 were 
cloned together with the 
two “swapped” cDNAs 
broken at the 219 aa. (for 
the human) or 223 aa. (for 
the mouse). Finally, also a 
truncated version of mouse 
Rnaset2 was cloned. 
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ANIMAL TUMOR MODELS 
Housing, treatment, and killing of animals followed national legislative provisions for the 
protection of animals used for scientific purposes and the ministry of health approved the 
protocol.  
C51 Empty cl. 10, C51 mRnaseT2 truncated cl. 6 and C51 mRnaseT2 full cl. 40 (0.2 x 106) cells 
were subcutaneously (s.c.) implanted in 7-week-old immunocompetent syngeneic BALB/c mice 
(Envigo). Tumor growth was daily monitored. The tumor volume was determined using the 
formula: (d)2 × D × 0.52, where d and D are the short and long dimension (cm) of the tumor, 
respectively, measured with a calliper. Euthanasia was performed when the tumor reached a 




Human mammary organoids were isolated from tissues obtained from informed healthy 
patients, undergoing mammoplasty reduction procedure. The enrolment was performed at the 
University of Athens, Greece, at the Department of Breast Cancer Surgery, Hospital "Agios 
Savvas" following the approval of Clinical Ethical Committee released by the Ministry of Health 
of Athens (CEC n. 01072016). Patient consent for the use of their specimens in research was 
obtained. The consent document informs the patients that the donated specimens will be used 
to study mammary SC differentiation and tumor initiation and progression. The research was 
performed in compliance with the Helsinki Declaration for experiments involving humans (The 
Code of Ethics of the World Medical Association).  
Isolation of human mammary organoids 
Mammary tissue, handled using the appropriate biosafety precautions, is transferred kept on 
ice, from operating room into a clean, sterile tissue culture hood. Adipose tissue is removed 
with scissors and tissue is cut in pieces of approximately 3–5 mm as described in Piscitelli Et al 
2015 [35]. 1–2 g of tissue is transferred to a 15-ml conical polypropylene tube filled with 10 ml 
collagenase (Sigma) solution. Tubes are incubated overnight on a rotator at 37 °C until the 
tissue fragments are dissociated. The following day tubes are removed from the incubator and 
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organoids, composed of luminal epithelial and myoepithelial cells are collected to a fresh tube 
by filtration. Organoids are washed with 10 ml PBS and centrifuged (300xg at 4 °C) for 5 min 
three times.  
Lentiviral particle production  
GFP reporter vector construction (pCDH-CMV-MCS-EF1-copGFP from SBI) and lentiviral 
particles were generated as described in Pelucchi et al. 2013 [36].  
Lentiviral-mediated transduction of shRNASET2-GFP into human breast organoids.  
10 organoids are transferred to one Eppendorf tube or to well of a six-well plate. 105–107 
colony-forming units of lentiviral particles plus 8 µg/ml of polybrene are added to the 
organoids, and the tube or the plate are spin at 32°C at 300g for 2hrs. Organoids are placed at 
37°C for 30 min. 1 ml of pre-warmed organoid medium is added and organoids are incubated 
overnight at 37 °C. The following day organoids are expanded for GFP expression. 
3D-organoid expansion  
Organoids are expanded by embedding them in 100 μl ice-cold Growth Factor Reduced 
Matrigel (BD Biosciences) at the concentration of 5-8 organoids /well in 48-well-plates (Greiner, 
Twin-Helix). Organoid medium (Ham’s F12/DMEM-GlutaMAX (1:1) containing 1X NEA-MEM 
(Invitrogen), 1 μg/mL insulin, 0.5 μg/mL hydrocortisone, 10 ng/mL EGF (Sigma), and 4 ng/mL 
bFGF (ImmunoTools) is added to the solidified Matrigel and then replaced every 3 days. 
Organoids are generated and re-passaged every 7-10 days. Cells during organoid formation 
assay were monitored with a fluorescence microscope (Olympus IX51) to characterize cell 
morphology and cell number. 
Matrigel dissociation for intact organoid recovery 
Disaggregation of Matrigel consists in several incubations of the organoids for 10 min each in 
ice, followed by a centrifugation at 0.4 g for 5 mins. This step is repeated until complete 


































Part I: RNASET2 effect on in vitro macrophages polarization 
Our previous experimental evidences allowed us to describe RNASET2 as a tumor suppressor 
gene, acting primarily in a non cell-autonomous manner in the context of an in vivo model of 
human ovarian carcinoma. Indeed, RNASET2-overexpressing tumors showed a marked decrease 
in their tumorigenic potential associated with a high infiltration by murine macrophages in 
xenograft-based assays. Moreover, in vivo host macrophages depletion in nude mice before 
human cancer cell inoculation led to a massive decrease of the observed RNASET2-dependent 
tumor suppressive activity [19,21]. Finally, using a human leukemic monocytes-derived cell line 
as an experimental model, we also reported a strong chemotactic role carried out by 
recombinant RNASET2 in in vitro migration assays [21]. 
Taken together, these data led us to hypothesize that cancer cell-derived RNASET2 protein acts 
by actively recruiting to the tumor mass cells from the monocytes-macrophages population 
endowed with anticancer properties, as suggested by the M1 polarization pattern observed in 
macrophages infiltrating RNASET2-overexpressing tumors in vivo. 
These data prompted us to investigate the putative role of the RNASET2 protein not only in 
monocyte/macrophage recruitment, but also in macrophage polarization. This issue is of key 
relevance, since tissue macrophages have long been known to carry out either pro- or anti-
tumoral activities based on their polarization pattern [18]. 
To address this issue, we therefore decided to establish a suitable in vitro experimental model 
that might help us to better define the mechanism by which RNASET2 could affect this cell 
population’s functional properties in vivo. 
To this aim, we chose the THP-1 human cell line, a well-established cell model which 
shares many properties with normal human monocytes and has been frequently used for 
investigations on macrophages’ differentiation and polarization pattern. 
Since previous experimental analysis in our lab had shown a high endogenous level of RNASET2 
expression in this cell line, in order to study of the effect of human RNASET2 in macrophages 




interference. As shown in figure 6, the chosen protocol led to a complete silencing of endogenous 
RNASET2 expression in THP-1 cells, as evaluated by western blot analysis. 
 
Figure 6. Analysis of RNASET2 protein expression in THP-1 RNASET2-silenced 
clones. 
Western blot analysis for RNASET2 expression in parental (lane 1) and 
RNASET2-silenced (lane 2) human THP-1 cells. Upper panel: an intracellular 
lysate was analyzed for RNASET2 expression. Lower panel: the same blot was 
probed with anti-tubulin polyclonal antibody for normalization.  
Image from: Scaldaferri et al. Immunol Lett. 2018. 
 
 
Thereafter, we proceeded with the differentiation of THP-1 cells into M0 macrophages by 
culturing them in 5 ng/ml PMA-containing medium, as described in Material and Methods.  
The effective differentiation of THP-1 cells in mature macrophages was verified and confirmed 
by both microscopy analysis and a real-time PCR assay, which showed both the expected shift in 
cellular behavior from suspension to adherence growth pattern and a marked increase in the 















Figure 7. Assessment of PMA–induced macrophage differentiation. 
A) Morphological changes associated with PMA–induced THP-1 cells differentiation into macrophages. 
Representative images are shown for PMA-treated (bottom panel) and vehicle-treated (DMSO, 
“CONTROL” – upper panel) cells at 20x magnification. 
B) Real time PCR analysis was also performed to determine the expression changes of the macrophage 





Both parental and RNASET2-silenced THP-1-derived M0 cells were then polarized into either M1 
or M2 macrophages as described in Material and Methods and the induced polarization pattern 
was investigated by real time qPCR to evaluate the expression level of known M1 (TNF and 
CXCL10) and M2 (CCL22 and CCL17) markers. 
As expected, we observed a marked increase in the expression of both M1 markers following 
LPS/IFN treatment, suggesting a proper M1-polarization in parental THP-1 cells (figure 8, black 
bars in upper panel). 
Of note, RNASET2 silencing turned out to attenuate M1 polarization these cells: indeed, whereas 
we observed a 50- and 5-fold increase in the expression levels of CXCL10 and TNF markers, 
respectively, when compared to unpolarized M0 cells in THP1 parental cells, the observed 
increase in the expression levels of both M1-specific markers was much more weak following 
RNASET2 knockdown (by 62% for CXCL10 and 28% for TNF, respectively) (figure 8, black bars in 
upper panel). 
These data suggest that the high levels of endogenous RNASET2 expression in THP-1 cells makes 
them particularly sensitive to M1-polarizing stimuli, since silencing of this gene leads to a 
weakened M1-response. 
By contrast, treatment with IL-4 turned out to be much less effective in driving M2 polarization 
in parental THP-1 cells, whose expression levels for both CCL22 and CCL17 markers showed a 
mere 1,5-3-fold increase when compared to unpolarized M0. 
By contrast, both CCL22 and CCL17 expression levels turned out to be dramatically increased in 
RNASET2-silenced cells (by 80- and 7-fold, respectively), as shown in figure 8 (white bars, lower 
panel). These data seem to provide a complementary picture of the M1 polarization pattern, 
since the high endogenous RNASET2 expression level in parental THP-1 cells apparently makes 
them almost unresponsive to M2-polarizing stimuli, and such unresponsiveness is lost following 
RNASET2 silencing. 
Taken together, these data are in keeping with the notion of RNASET2 acting as a macrophage-


























Figure 8. qRT-PCR analysis for M1 and M2 polarization markers in THP-1-derived human macrophages. 
Total RNA was isolated from polarized parental (black bars) or RNASET2-silenced (white bars) THP-1-
derived macrophages from each experimental group. Following reverse transcription, a real time qRT-PCR 
assay was carried out to analyze the expression changes of 4 different markers of macrophages 
polarization, using GAPDH as an internal standard. 
Gene expression levels are plotted as fold difference in mRNA expression versus THP-1 parental M0 set 
as 1.0. Error bars represent standard deviation from the mean. Statistical analysis was performed as 
described in Materials and Methods. *P<0. 05; **P<0. 01; ***P<0. 01. M1 markers: CXCL10 and TNFα; M2 
markers: CCL22 and CCL17. Image from: Scaldaferri et al. Immunol Lett. 2018. 
 
The data described above have been obtained following the experimental manipulation of the 
endogenous expression of RNASET2 in THP-1 cells. However, since RNASET2 is described as an 
extracellular protein, it is difficult to define whether the observed effect of the gene’s silencing 
on the THP-1 cell’s polarization pattern was mediated by RNASET2 acting within the target cells 
themselves or rather by means of an autocrine mechanism based on RNASET2 secretion followed 




Indeed, in our in vivo xenograft-based assays the observed recruitment of host macrophages was 
induced by cancer cell-derived extracellular RNASET2, suggesting a non-cell autonomous 
mechanism of action for this protein. 
To better clarify this issue, we decided to test the effect of exogenously added recombinant 
RNASET2 on the polarization pattern of THP-1 cells.  
To this aim, RNASET2-silenced THP-1 cells were differentiated into M0 macrophages and 
subsequently polarized into M1 and M2 subtypes in the presence or absence of Pichia pastoris-
derived recombinant RNASET2 protein, previously produced in our lab [34]. Since we could not 
foresee if macrophages exposed to strong M1-inducing cytokines would also be responsive to 
recombinant RNASET2 treatment, three different M1 polarization regimens (i.e., LPS/IFN , LPS 
alone and IFN  alone) were applied to THP-1 cells in order to better tune the M1 polarization 
process. Moreover, a third M1 polarization marker (CCL-19) was included in our qPCR assays, 
whereas the classical M2-specific MRC1 marker was used in place of CCL17. 
As shown in figure 9, most M1-polarizing stimuli led to the expected increase in the expression 
level of the corresponding M1 markers in the absence of recombinant RNASET2 (white bars, 
upper lane). As for the M2 polarization, we observed an effective increase of the CCL22 marker, 
whereas only a weak increase in the expression level of MRC1 was accomplished (white bars, 
lower lane).  
Of note, treatment of RNASET2-silenced THP-1 cells with the recombinant protein led to a slight 
but consistent increase in the expression level of M1-like specific markers under most M1-
polarizing regimens (arrow-marked black bars, upper lane). At the same time, treatment with 
recombinant RNASET2 led to a decrease of both M2 polarization markers, which was particularly 
evident for MRC1. 
Thus, in keeping with the working hypothesis developed from our previous in vivo studies, 
exogenously added recombinant RNASET2 was also able to affect the polarization pattern of THP-
1-derived macrophages, although the observed effect was not as marked as the one observed 
following manipulation of the endogenous RNASET2 levels. The putative reasons for such 





Figure 9. Real time qRT-PCR analysis for M1 and M2 polarization markers in RNASET2-silenced THP-1-
derived macrophages in the presence or absence of recombinant RNASET2 protein. 
Total RNA was isolated from RNASET2-silenced, M0, M1- or M2-polarized THP-1 macrophages grown in 
the presence or absence of recombinant RNASET2. The RNA was reverse transcribed, and a real time qRT-
PCR assay was carried out to analyze the expression of 5 different markers of macrophages polarization, 
using GAPDH as an internal standard. Black arrows point to the experimental groups where treatment 
with recombinant RNASET2 resulted in an increase of M1 marker expression and a decrease in M2 marker 
expression. Gene expression levels are plotted as fold difference in mRNA expression versus THP-1 SH 
RNASET2 M0, not treated with recRNASET2, set as 1.0.M1 markers: CXCL10, TNFα and CCL19; M2 markers: 
CCL22 and MRC1. Image from: Scaldaferri et al. Immunol Lett. 2018. 
 
Our data with the human THP-1 cell line strongly suggest that RNASET2 affects the 
macrophage polarization pattern in vitro. To further validate these data, we carried out a 
preliminary investigation on freshly prepared human PBMC-derived macrophages. PBMC-
derived human monocytes were isolated from buffy-coat samples from five independent healthy 
donors and the homogeneity of the isolated monocyte cell population was assessed by 
cytofluorimetric analysis, which showed that CD14-positive cells in all preparations represented 
more than 90% of the total cells (data not shown). The isolated monocytes were then 
differentiated in vitro to macrophages by culturing them in M-CSF-containing medium for 6 days. 
The effective differentiation of these cells into M0 macrophages was confirmed by both light 
microscopy and a qPCR assay showing an expected decrease in the expression levels of the CCR2 






Figure 10. Assessment of the differentiation pattern in PBMC-derived human macrophages. 
A) Morphological changes associated with M-CSF–induced monocyte/macrophage differentiation. 
Representative images are shown for M-CSF treatment (bottom panel) and for control (upper panel) at 
20x magnification. B) Real time PCR analysis results showing the expected expression change of the 
macrophage differentiation marker CCR2 during macrophage differentiation. Image from: Scaldaferri et 
al. Immunol Lett. 2018. 
 
To evaluate the putative occurrence of significant differences in the endogenous expression 
level of RNASET2 among the different samples, a real time qPCR analysis was carried out to 
compare the expression profile of PBMC-derived monocytes and M0 macrophages from all 
donors with that of THP-1 cells. The endogenous RNASET2 expression levels in the monocyte 
population from five donors turned out to be very similar to that observed in naïve THP-1 cells 
(figure 11).  
 
Figure 11. Real time qRT-PCR analysis for RNASET2 
expression in THP-1- and PBMC-derived monocyte. 
Total RNA was isolated from both parental/RNASET2-
silenced THP-1 and PBMC-derived monocytes. The RNA 
was reverse transcribed and a real time qRT-PCR assay was 
carried out to analyze the expression of the RNASET2 gene, 
using GAPDH as an internal standard. Image from: 
Scaldaferri et al. Immunol Lett. 2018. 
 
 
Therefore, the monocyte population from these five donors was selected for a preliminary 




M0 macrophages were induced to polarize into M1 or M2 macrophages following treatment 
with IFN- /LPS or IL4, respectively, in the presence or absence of human recombinant RNASET2, 
as described in Materials and methods.  
To evaluate the efficacy of the applied polarization procedure and the effect of RNASET2 
treatment on cell polarization pattern, a real time PCR analysis was performed to evaluate the 
expression of two M1-specific (CXCL10 and TNF- ) and two M2-specific (CCL17 and MRC1) 
markers. 
Unfortunately, in the macrophage populations derived from all five donors the expected 
pattern of M1 polarization following IFN- /LPS treatment was observed for one donor only (figure 
12). These results are possibly attributable to the well-known issue of donor-to-donor variability 
inherent to human PBMC-derived monocytes. 
Of note, when the effect of human recombinant RNASET2 administration was evaluated in 
IFN- /LPS treated monocytes, one of the five donors showed a marked increase of the CXCL10 
marker expression following treatment with recombinant RNASET2 (figure 12). Moreover, when 
the expression of the same M1 polarization markers was evaluated in M2-polarized 
macrophages, a clear trend supporting an effect of recombinant RNASET2 was observed. Indeed, 
in all five donors both M1-specific markers (CXCL10 and TNF-  showed a consistent trend 






Figure 12. Real time qRT-PCR analysis for M1 polarization marker expression in PBMC-
derived macrophages in the presence or absence of recombinant RNASET2 protein. 
Total RNA was isolated from M0, M1- and M2-polarized macrophages from five independent 
donors, reverse transcribed as described in Materials and Methods and analyzed by real-time qRT-PCR 
assay to evaluate the expression of two different markers of M1 macrophages polarization (CXCL-10 and 
TNF-α) under each experimental condition, using GAPDH as an internal standard. Gene expression levels 
are plotted as fold-change differences in mRNA expression using macrophages M0 without recRNASET2 
as a reference set as 1. Image from: Scaldaferri et al. Immunol Lett. 2018. 
 
Thus, even though PBMC-derived macrophages did not show a proper M1 polarization 
response following IFN- /LPS treatment, recombinant RNASET2 was nevertheless associated 






Figure 13. Increase in M1 markers in PBMC-derived M2 macrophages with recombinant RNASET2  
Data in figure 5 plotted as donors with and without recombinant RNASET2, with a Mann-Whitney two 
tailed test was used to compare the data. A statistically significant increase in M1 markers in PBMC-
derived M2 macrophages was apparent. Image from: Scaldaferri et al. Immunol Lett. 2018. 
 
When we turned our attention on the expression profile of M2 polarization markers in PBMC-
derived macrophages, although IL-4 treatment was highly effective in triggering a M2-
polaritazion response in all samples, the effect of recombinant RNASET2 was very difficult to 
define. Indeed, MRC1 expression turned out to be largely unaffected in M2 macrophages, 
whereas CCL17 expression showed a marked donor-dependent trend for either an increase or a 
decrease in its expression level (data not shown).  
These very preliminary experiments in PBMC-derived macrophages were therefore quite 
inconclusive and did not provide clear-cut results comparable to those observed in RNASET2-
silenced THP-1 cells, likely due to the well-known phenomenon of donor-to-donor variability 
when using PBMC-derived cells. However, notwithstanding the intrinsic limitations of this 
approach, we were still able to observe a trend for an RNASET2 effect on PBMC-derived 
macrophages as well, prompting us to repeat the investigations on this in vitro polarization model 








Part II: Interplay of RNASET2 with the tumor microenvironment in 
an immunocompetent mouse 
 
So far, the in vivo experiments aimed at characterizing the oncosuppressive activity of RNASET2 
have been carried out by injecting immunocompromised mice with human ovarian cancer cells. 
Xenograft-based assays represent a widely used experimental model in cancer research, given 
their potential to faithfully recapitulate several features of the carcinogenic process in vivo.  
On the other hand, these models suffer from the key limitation of making use of animals whose 
immune system is inactivated to different extents.  
Given the prominent role of both innate and adaptive immune systems in modulating the growth 
rate of cancer [6] and the results from our previous experiments, pointing to a functional 
crosstalk between RNASET2 and cellular components of the immune system, we decided to 
further investigate the oncosuppressive role of RNASET2 in vivo in the context of a totally 
immunocompetent experimental model.  
This would represent a key task to expand our knowledge on the physiological mechanisms 
underlying RNASET2-mediated tumor suppression and at the same time to shed light on its 
putative interaction with all component of the host immune system. 
Based on these premises, we therefore sought to investigate the role of RNASET2 in a syngeneic 
mouse model. 
 
ANALYSIS OF RNASET2 ENDOGENOUS EXPRESSION IN DIFFERENT MOUSE CELL LINES 
To this end, we first assessed the endogenous expression levels of the orthologous Rnaset2 gene 
in different murine cell lines, by comparing them with multiple human cell lines routinely used in 





Figure 14. Immunoblot probed with polyclonal antibody anti-RNASET2 and anti-tubulin 
Upper panel: intracellular lysates of different murine cell lines were analysed for RNASET2 expression. A 
very low level of endogenous expression was observed when compared with other cell lines commonly 
used in our lab. Lower panel: the same blot was probed with anti-tubulin antibody for normalization. 
 
Quite unexpectedly, the expression of RNASET2 turned out to be quite low in all the murine cell 
lines tested. 
Based on our previous experience with RNASET2-negative human cancer cell lines [16], we 
therefore decided to carry out transiently transfection assays to overexpress both human and 
murine RNASET2 proteins in three different murine cell lines (C51, ID8, TS/A) and one human cell 
line (Hey3Met2), using a plasmid bearing a constitutive promoter as described in Materials and 
Methods. To our surprise, whereas the human RNASET2 protein was efficiently overexpressed in 
all cell lines tested, the murine protein was never expressed (figure 15).  
The putative inefficacy of our rabbit polyclonal anti-RNASET2 antibody (which had been raised 
against the human protein) to recognize the murine protein was ruled out, since we were able to 
easily detect murine RNASET2 by western blot analysis on protein extracts from two different 
adult murine tissues (heart and kidney, arrow-marked bands in figure 15, right panel).  
Figure 15. Immunoblot probed with polyclonal 
antibody anti-RNASET2 
Total protein extracts from transiently transfected 
cells were analyzed for RNASET2 expression. In all 
four cell lines tested, the human RNASET2 protein 
was expressed whereas the mouse Rnaset2 was 
never detected. As a control, protein extracts from 
two murine tissues were loaded and the protein was 


































Therefore, we hypothesized that, unlike human RNASET2, constitutive expression of the murine 
orthologous gene might result in a toxic or growth-suppressing effect on the cells.  
 
EXPRESSION OF MOUSE RNASET2 USING AN INDUCIBLE EXPRESSION VECTOR. 
We therefore decided to turn to an inducible expression vector bearing either the human or the 
murine cDNA. We bought a customized commercial vector bearing the mouse Rnaset2 cDNA and 
the genetic elements needed for inducible transgene expression with the Tet-on system. 
Moreover, we added a 3xFLAG tag-coding sequence at the 3’ end of the Rnaset2 cDNA in order 
to detect the corresponding protein with a different antibody. Finally, we chose this vector to be 
a bicistronic construct, allowing co-expression of the reporter GFP protein with Rnaset2. This was 
meant to allow us to understand if the Rnaset2 transcript itself was expressed. As a control, we 
cloned the human RNASET2 cDNA in the same vector. A schematic representation of the vector 
is shown in Figure 4 of materials and methods. 
 
The murine TS/A cell line was chosen for inducible RNASET2 expression assays, so we first 
transiently transfected the inducible plasmids into these cells. 24 hours after the transfection, 
RNASET2 expression was induced by doxycycline treatment for 24 hours. By checking expression 
of the GFP reporter using fluorescence microscopy, we observed only a few positive cells for both 
constructs (Figure 16a). Moreover, when we tested protein extracts from these cells by western 





Figure 16. Analysis of TS/A cell line transiently transfected with inducible vectors bearing human or 
mouse RNASET2 
The murine TS/A cell line was transfected with both the inducible vector for the expression for human 
RNASET2 and the same vector for the expression of the murine protein. After 24 hours, the expression 
was induced with doxycycline at three different concentrations. Cell were analyzed at the fluorescence 
microscopy and then protein extracts were produced and analyzed by immunoblot analysis. A) 
Representative images of positive GFP cells in the lower panel. B) Total protein extracts were analyzed for 
RNASET2 expression: cells transfected with the plasmid bearing the human cDNA expressed the protein 
at all the concentrations, whereas no expression was found when transfected with the mouse-bearing 
one. 
 
We nevertheless went on to stably transfect the cells, in order to enrich for cellular pools bearing 
the inducible plasmids and then induce them.  
Since the vectors carry a neomycin resistance gene as a selectable marker for eukaryotic cells, 
we tested the toxicity of the selective antibiotic G418 on TS/A cells before transfection. Once the 
optimal G418 concentration to be used for clone selection was estimated to be 300 µg/ml, we 
proceeded with stable transfection. The transfected cells were subsequently detached from the 
6-wells plate, re-suspended in fresh medium supplemented with the selective agent G418 and 
seeded.  Following a 14-days period of selection, we obtained a pool of G418-resistant clones 
that were induced for 48 hours with Doxycycline at 1 µg/ml of concentration. 
Although the observation of cells under fluorescence microscopy confirmed the functionality of 




untreated cells, which showed a weak expression of GFP even in absence of the inducer (figure 
17).  
 
Figure 17. Analysis of GFP expression in TS/A cell line stably transfected with inducible vectors 
The murine TS/A cell line transfected with the inducible vectors bearing the human or mouse RNASET2 
cDNA were induced with doxycycline for 48 h. Cell were analyzed at the fluorescence microscopy: GFP 
positive cells are present in both the pool of clones, but a weak leaking expression is also visible in 
untreated (“-DOX”) cells. 
 
This phenomenon, which was not observed following transient transfection, was confirmed by 
western blot analysis using both an anti-RNASET2 and anti-FLAG antibody (figure 18) and by FACS 




Figure 18. Immunoblot analysis of RNASET2 expression in pool of 
clones of the TS/A cell line stably transfected with inducible vectors 
Total protein extracts from transfected clones were analyzed for the 
expression of RNASET2. Again, only cells transfected for the human 
RNASET2 protein were positive.  
An anti-FLAG antibody was also used and the result is the same: the 
mouse protein isn’t expressed. Unfortunately, a minimal expression of 
RNASET2 is also present in untreated cells. Specific signals were 






Figure 19. Cytofluorimetric analysis of GFP positive cells in TS/A parental cells and pool of clones 
Pool of clones were analyzed for percentage of GFP positive cells. Differences between untreated and 
treated cells were very small, probably due to the leaking expression phenomenon. A) TS/A parental; B) 
TS/A inducible vector with hRNASET2 untreated; C) TS/A inducible vector with hRNASET2 treated with 
doxyxicline; D) TS/A inducible vector with mRnaset2 untreated; C) TS/A inducible vector with mRnaset2 
treated with doxyxicline. 
 
Most importantly, besides the vector leakiness problem, the expression of mouse Rnaset2 was 
still not detectable by western blot analysis using both anti-RNASET2 and anti-FLAG antibodies 
(with the latter specifically used to recognize with the same efficiency the human and mouse 
proteins).  
On the basis of these results, we decided to move our expression analysis at the transcription 
level. Total RNA from stably transfected pools of clones was extracted, reverse transcribed into 
cDNA and used for a qPCR analysis with primers designed on the 3xFLAG coding sequence.  
As shown in figure 20A, we observed a 2-fold expression increase in cells treated with doxycicline 
at 1 µg/ml for 48 h.  Interestingly, this increase, though weak, was observed in cells transfected 
with both the human and murine RNASET2 expression vectors. We considered this as an 
indication that the murine transcript was properly produced with this system, although we were 




As a further evidence that the RNASET2 transcripts were expressed and intact, we carried out a 
classical RT-PCR on the same cDNAs with primers crossing the IRES region, with the forward 
primer designed on the RNASET2 3xFLAG sequence and the reverse primer on the GFP sequence. 
In keeping with our previous RT-PCR data, the bicistronic transcript was observed in all the 
samples (figure 20b). 
 
Figure 20. qRT-PCR analysis of the expression levels of the transcripts and classical PCR with primers 
spanning the IRES region 
Total RNA was isolated from TS/A clones untreated or treated with doxycycline, reverse transcribed and 
used for both a quantitative PCR with primers designed on the 3xFLAG coding sequence and a classical 
PCR to verify the integrity of the transcript cDNA-IRES-GFP. A) Gene expression levels are plotted as fold 
difference in mRNA expression versus untreated TS/A transfected with the inducible vectors bearing the 
human cDNA set as 1.0. The addition of doxycycline increased the expression of the transcript, even 
though of only 2-fold, in cells transfected both for the human or mouse protein. B) Further evidence 
supporting the presence and integrity of the transcript were provided by a classical PCR using a forward 
primer on the region of the transcript before the IRES sequence and a reverse primer on the region after 
that sequence: the expected PCR amplicon was detected in all samples. 
 
Taken together, these data seemed to suggest the occurrence of a functional difference of 
murine versus human RNASET2, at least in the context of in vitro transfection assays. 
To exclude a cell-line specific effect for this unexpected observation, a second murine cell line 
(C51) was transiently transfected with both plasmids but the results were still consistent with 
overexpression of the human protein only (data not shown). 
Overall, these data confirmed the difficulties in expressing the murine Rnaset2 protein in these 
experimental models and, at the same time, suggested that the underlying problem could reside 





PROTEIN SWAP APPROACH 
In the light of the observed discrepancy in the expression efficiency between the human and 
mouse T2 RNase protein, we turned to a “protein domain swap” approach in the attempt to map 
the putative region from murine Rnaset2 responsible for this biological difference. 
For this purpose, we aligned the primary sequence of the human RNASET2 protein with the 
sequences of the two mouse Rnaset2 (A and B) isoforms (the latter derive from two different 
genes whose coding sequence are identical). The human and mouse proteins show a 67% identity 
and 79% similarity. However, a putative TRAF-binding motif (PKQE), which has been reported to 
be potentially involved in RNASET2-mediated cell apoptosis [37], was not detected in the 
orthologue mouse protein (figure 21). 
We therefore decided to break the human protein at the 219 aa residue, therefore excluding the 
TRAF2 binding domain that is absent in the mouse protein. Reciprocally, we interrupted the 
mouse protein at the 223 aa, as described in figure 21. 
 
Figure 21. Primary sequences alignment of the human RNASET2 with the mouse Rnaset2A and Rnaset2B 
The three sequences were aligned using the ClustalOmega program. Signal peptides, CAS sites 
(represented by the two histidines in the green boxes) and the TRAF2 binding site are indicated. The 





Besides the issue concerning the TRAF-binding site, the decision to interrupt both proteins in that 
point was based on their tertiary structure as well. Indeed, although bioinformatics prediction 
tools suggest that the mouse protein should have a quite similar structure to the human one, the 
C-terminal region, which include the putative TRAF2 binding site, appear to be the most 
unstructured and disordered and it should accordingly withstand a domain swap manipulation 
(figure 22) [38]. 
 
 
Figure 22. 3D structures of the human RNASET2 and the mouse Rnaset2 proteins 
The 3D structure of the human RNASET2 protein (A) has been determined by X-ray cristallography [38 – 
Image from Nucleic Acids Res. 2012 Sep; 40(17): 8733–8742], whereas the mouse protein structure (B) 
has been predicted by the SWISS model bioinformatic tool. 
 
Since we could not successfully address the problem of absent murine RNASET2 expression using 
an inducible expression vector, we turned back to the constitutive pcDNA3 expression vector, 
which has been successfully used in our lab for most RNASET2-overexpression assays in the past. 
Following the addition of a 3xFLAG coding sequence in the vector’s backbone (see Materials and 
Methods) we cloned into this vector five independent RNASET2 coding sequences:  
(1) a full-length human RNASET2 cDNA 
 (2) a full-length mouse Rnaset2 cDNA 
 (3) a truncated version of mouse Rnaset2 coding region, spanning aa 1-223 
 (4) a chimeric version with the human RNASET2 sequence including aa 1-219 followed by the 




(5) a complementary chimeric version, with the murine RnaseT2 sequence spanning aa 1-223 
followed by the human protein sequence spanning aa 220-256 (“N-ter mouse/C-ter human”).  
A schematic representation of these five expression plasmids, assembled following the protocol 
described in materials and methods, is shown in figure 5. 
All these recombinant constructs were transiently transfected into the TS/A cell line. After 24 
hours, total protein extracts were prepared, quantified and analyzed by western blot. Using both 
the anti-RNASET2 and anti-FLAG antibody, we detected a strong signal for the human full-length 
and a weaker signal for the chimeric N-ter human/C-ter mouse proteins, respectively (figure 23). 
This preliminary result seemed to point to the mouse N-terminal region as the one responsible 
for the previously observed lack of expression.  
 
 
Figure 23. Western Blot analysis of TS/A transiently transfected 
Total protein extracts were analysed for RNASET2 expression. The anti-FLAG antibody was used as further 
analysis. In both cases, we observed positivity only for the cells transfected with the vector bearing the 
full-length human RNASET2 and with the vector bearing the chimeric region N-ter human/C-ter mouse. A 
























































































































On the basis of these data, we decided to produce stably transfected pools from both C51 and 
TS/A cell lines and to subsequently analyze RNASET2 expression on both protein extracts and 
supernatants. 
As show in figure 24, switching from transient to stable expression assays substantially confirmed 
the previous data, since a clear expression signal was mainly observed for both the human full-
length protein and the N-ter human/C-ter mouse chimeric protein in TS/A cells. However, a faint 
band corresponding to the N-ter mouse/C-ter human was observed in both cell extracts and 
supernatants as well. Interestingly, a weak signal was also observed in cells transfected with the 
vector bearing the mouse truncated cDNA (arrow mark). 
Figure 24. Western Blot analysis of 
TS/A stably transfected pools 
(A) Total protein extracts were 
analysed with anti-RNASET2 and anti-
FLAG antibodies. In both cases, we 
observed clear positivity for cells 
transfected with the vector bearing the 
full-length human RNASET2 and with 
the vector bearing the chimeric region 
N-ter human/C-ter mouse. Moreover, a 
weaker band was observed for cells 
transfected with N-ter mouse/C-ter 
human cDNA. (B) The analysis of the 
supernatants with the anti-RNASET2 
antibody confirmed the results. 
 
When the same vector series was used to transfect the C51 cell line the results were quite 
comparable, except for the detection with the anti-FLAG antibody of a band corresponding to 

















































































































































































































Figure 25. Western Blot analysis of C51 
stably transfected pools 
(A) Total protein extracts were 
analysed with anti-RNASET2 and anti-
FLAG antibodies. In both cases, we 
observed clear positivity for cells 
transfected with the vector bearing the 
full-length human RNASET2 and with 
the vector bearing the chimeric region 
N-ter human/C-ter mouse. Moreover, a 
weaker band was observed for cells 
transfected with N-ter mouse/C-ter 
human cDNA. Interestingly, the anti-
FLAG antibody revealed a weak band 
also for cells transfected with the 
truncated version of the mouse 
Rnaset2. (B) The analysis of the 
supernatants with the anti-RNASET2 antibody were consistent with that of TS/A cell line pools. 
 
A quantitative PCR analysis carried out on all transfectants showed a slight decrease of mouse 
full-length and truncated transcripts (figure 26), but this result was apparently not sufficient to 
explain the marked difference observed by western blot analysis, once again suggesting the 
occurrence of a post-transcriptional event to explain the absent or reduced expression of the 
murine protein. 
 
Figure 26. qRT-PCR analysis of the expression levels of the transcripts in TS/A and C51 pools 
Total RNA was isolated from TS/A and C51 pools of clones, reverse transcribed and used for both a 
quantitative PCR with primers designed on the 3xFLAG coding sequence. Gene expression levels are 
plotted as fold difference in mRNA expression versus cells transfected with the human cDNA set as 1.0.  
 
 
Taken together, the data from our transfection series confirmed the extreme difficulty to express 
























































































































































































































































































assign such phenomenon to a particular region of the murine protein, since we could observe 
expression of both the N-ter human/C-ter mouse and N-ter mouse/C-ter human chimeric 
proteins, although at a quite weak level when compared to the human full-length protein. 
However, the observation of a weak expression of the mouse truncated protein suggested that 
some cells could express even the full-length murine Rnaset2, although to a weaker level 
compared to human RNASET2, and that by using pool of transfected cells such putative weak 
expression could pass unnoticed.  
We therefore decided to generate single murine Rnaset2-transfected stable clones in both 
murine cell lines and to screen a very high number of clones in the hope to obtain a few murine 
Rnaset2-expressing clones. 
Indeed, as shown in figures 27 and 28, following an intensive screening of stably transfected C51 
and TS/A clones (70 and 60 clones), we were finally able to select a few clones expressing low to 
moderate levels of both truncated and full-length murine Rnaset2. 
 
Figure 27. Western blot analysis of C51 single stable clones 
Total protein extracts were analysed with anti-FLAG antibodies. Representative images for screening of 
clones overexpressing the mouse truncated (A) or full-length (B) protein. When some clones were 
positively selected, the anti-humanRNASET2 antibody was also used for analyzing the same clones but we 
























































































































































































































































































































Figure 28. Western blot analysis of TS/A single stable clones 
Total protein extracts were analysed with anti-FLAG antibodies. Representative images for screening of 
clones overexpressing the mouse full-length (left panel) or truncated (right panel) protein.  
 
The overexpressing clones were also analysed with the anti-RNASET2 antibody, but 
unfortunately, this antibody has not the same efficiency to detect the mouse orthologue protein 
as to detect the human one (figure 27c). 
We next decided to test murine Rnaset2-expressing clones (both truncated or full) for their in 
vitro cell proliferation rates. As shown in Figure 29 (left panel), a significant decrease in cell 
growth was observed for C51 cells overexpressing the full-length murine protein when compared 
to the control cells. Interestingly, the decrease in cell growth was slighter, and not statistically 
significant, in C51 cell clones expressing the truncated protein. 
 
Figure 29. Analysis of cell proliferation assay and western blot analysis of C51 single stable clones 
(A) Immunoblot analysis of mouse Rnaset2 overexpressing C51 cell clones with anti-FLAG antibody.  
(B) MTT assay: four clones for each experimental group were analyzed. An ANOVA statistical analysis was 























































































































































































































C51 cell proliferation assay







































































































































































When the same analysis was performed with TS/A clones, the same trend was observed, with 
mRnaset2 full length protein overexpression correlating with a modest decrease in proliferation 
rate, even though the observed difference was not statistically significant (figure 30). 
 
Figure 30. Analysis of cell proliferation assay and western blot analysis of TS/A single stable clones 
(A) Immunoblot analysis of mouse Rnaset2 overexpressing TS/A cell clones with anti-FLAG antibody.  
(B) MTT assay: three clones for each experimental group were analyzed.  
 
Finally, to further investigate the role of murine RNASET2, we performed a preliminary in vivo 
assay. Balb/c mice were injected subcutaneously with Rnaset2-expressing C51 clones previously 
investigated in vitro (one clone for each experimental group) and the tumor growth rate was 
followed for up to 18 days. Interestingly, large tumours developed in mice inoculated with empty 
vector-transfected cells or with vector expressing the truncated mRnaset2 form, whereas cells 
expressing the wild-type full-length form of mRnaset2 were clearly suppressed in their 
tumorigenic potential (figure 31). 
Though preliminary, these data represent the first experimental evidence supporting the in vivo 






Figure 31. Analysis of in vivo tumor growth rates of C51 cell clones 
One clone for each experimental group was inoculated s.c. in nude mice as described in Materials and 
Methods. Tumor growth was monitored every 2 d until day 40. At least three mice were inoculated for 
each tested clone. 
 
Part III: RNASET2 in the context of mammary morphogenesis and 
tumorigenesis 
 
So far, the oncosuppressive activity of the RNASET2 gene (both non-cell autonomous and 
cell-autonomous) has been mainly investigated in ovarian carcinoma models. However, since the 
RNASET2 gene maps to the 6q27 chromosomal region, which is reported to be frequently deleted 
or rearranged in several solid and hematological cancers, an interesting issue for future 
investigations concerns the role of RNASET2 in other cellular models of cancer, such as the 
mammary epithelium. Of note, a preliminary analysis of breast cancer relapse-free survival (RFS) 
data (Kaplan-Meyer plots) from the TCGA breast cancer patients’ collection showed a trend for a 
positive association between RNASET2 expression levels and higher RFS for both the total breast 
cancer sample and some cancer subtypes (figure 32), suggesting that RNASET2 expression might 































Figure 32. Kaplan-Meyer plots for Relapse-Free Survival (RFS) in breast cancer patients according for 
RNASET2 expression level 
The three curves show the RFS plots from the TCGA database for total breast cancer sample (left panel), 
Luminal-A breast cancer patients (middle panel) and HER+ cancer patients (right panel). 
 
Moreover, given the widely acknowledged pleiotropic roles reported for members of the 
T2 Rnase family, investigations on RNASET2’s tumor suppressive role in an independent cancer 
model might shed light on previously unrecognized mechanisms by which this versatile class of 
proteins operate in cancer cells. 
Within this frame, the human breast cancer cell line MCF7 was therefore chosen as an 
experimental model. Interestingly, analysis of RNASET2 expression in this cell line by western blot 
analysis showed that, compared to other cell lines previously used in our laboratory, MCF7 cells 
display very low levels of RNASET2 endogenous expression (figure 33). These findings prompted 






Figure 33. Immunoblot probed with polyclonal antibody anti-RNASET2 
Upper panel: intracellular lysate of MCF7 cell line was checked for RNASET2 expression. A very low level 
of endogenous expression is shown compared with other cell lines. Lower panel: the same blot was 
probed with anti-a-tubulin polyclonal antibody for normalization. 
 
2D IN VITRO ASSAYS 
We therefore proceeded to stably transfect MCF7 cells with our constitutive human 
RNASET2 expression vectors. The transfected cells were subsequently put in medium with a 
selective agent. Following a 2-weeks period of selection, single clones were picked-up, expanded 
and analyzed by western blot with an anti-RNASET2 antibody. On the basis of the observed 
expression levels, three clones from each experimental group were chosen for further 
investigations (figure 34).  
 
Figure 34. Immunoblot probed with polyclonal antibody anti-RNASET2 
Total protein extracts of MCF7 clones were checked for RNASET2 expression. Specific RNASET2 signals 






















































































































































































































































































































Once RNASET2-overexpressing clones were isolated, we first carried out a panel of 
standard cancer-related in vitro assays, such as cell proliferation and colony formation.  
By comparing the in vitro cell proliferation rates of RNASET2-overexpressing clones to that of 
control clones transfected with the empty vector (MCF7 pcDNA3 empty) a slight decrease in the 
proliferation rate of RNASET2-overexpresing clones was observed, with no statistical difference 
(figure 35a). 
This result was not completely unexpected, being in keeping with experimental data previously 
observed in our lab with some human ovarian cancer-derived cell lines. 
We then assessed the ability of the same clones to form colonies in culture dishes. Strikingly, this 
parameter was significantly decreased in RNASET2-overexpressing clones with respect to control 
clones, as shown in figure 35b. 
 
Figure 35. Analysis of cell proliferation rates and colony formation ability 
(A) A cell proliferation assay was performed in RNASET2-overexpressing clones and control cell clones 
using an MTT assay as described in Materials and Methods. Triplicate experiments were 
performed with three clones of each experimental group. Mean values of the three clones of 
pcDNA3 empty clones and pcDNA3-RNASET2 overexpressing clones. A slight variability in their 
proliferation rate was observed, but there was no statistical difference.  
(B) RNASET2-overexpressing MCF7 cell clones generated a smaller number of colonies than control 
cell clones in colony formation assay. Experiments were carried out on three independent clones 
for each experimental group and then mean value were considered. Mean value of control clones 
significantly differs from both RNASET2-overexpressing clones. 
 
We next decided to test whether RNASET2 overexpression could also affect apoptosis in MCF7 
cells. As shown in figure 36, in the absence of any particular apoptotic induction, RNASET2-
















































to control cells, although the fraction of apoptotic cells was very small in both samples. Again, 
these data are in keeping with those previously obtained in the ovarian cancer-derived OVCAR3 
cell line [24]. To better investigate the role of RNASET2 in the induction of apoptosis, we then 
challenged cell clones with 200 μM CoCl2: strikingly, an increased apoptotic rate was observed in 
RNASET2-overexpressing cell clones, although the effect was quite weak. Moreover, when cells 
were challenged with a non-physiological apoptogenic stimulus (100 nM cis-platinum) the 
percentage of apoptotic cells increased in both control and RNASET2-overexpressing cells, but 
the trend for an increased apoptotic rate in the latter cells was still detected. 
 
 
Figure 36. Analysis of cell-death rate in response to pro-apoptotic stimuli. 
Flow cytometry analysis was performed in RNASET2-overexpressing MCF7 cell clones with respect to 
control clones stained with propidium iodide, following a 24-hours treatment with either cobalt chloride 
or cis-platinum. In all of the three experimental conditions, RNASET2-overexpressing clones showed a 
percentage of apoptotic cells significantly higher than control clones. Three technical replicates were 
performed. Statistical analysis was performed using t-test student (assuming p<0.05 as a threshold value 
to discard the null hypothesis. 
 
RNASET2 CYTOPLASMIC LOCALIZATION AND PHALLOIDIN STAINING 
In a previous work carried out in ovarian cancer cells, a RNASET2-dependent cytoskeleton 
reorganization was reported [24]. Of note, the effect of RNASET2 on the cell cytoskeleton seem 
to represent an evolutionary conserved feature, since it has been reported for human RNASET2 
and for its two orthologues Omega-1 and ACTIBIND as well [20,25]. We thus investigated the 






























The observed actin staining profile was indicative of a complex network of actin filaments in 
clones overexpressing wild-type RNASET2, with several long actin-filament bundles crossing the 
whole cell length. Strikingly, this pattern was significantly altered in control clones, which showed 
a mainly peripheral actin filament bundle pattern instead (Figure 37). These data are totally in 
keeping with our recent findings in OVCAR3 cells and further suggest a prominent cell-
autonomous role for RNASET2 in the regulation of the cell cytoskeleton organization. 
Taken together, these data provide a first evidence that the cell-autonomous oncosuppressive 
role of RNASET2 that we previously reported in human ovarian cancer-derived experimental 
models can be faithfully recapitulated in a breast cancer cell model as well. 
 
 
Figure 37. Structural organization of the actin cytoskeleton 
MCF7 cell clones were seeded on coverslips and stained with TRITC-conjugated Phalloidin. A complex 
network of actin filaments is evident in RNASET2-overexpressing cells, while the actin cytoskeleton 
appears different in control clones. Details on Ph-TRITC stained cell (Confocal microscopy images). 
  
 
EVALUATION OF MAMMOSPHERE FORMATION IN 3D CULTURE CONDITIONS 
On the basis of the promising results obtained by investigating the role of RNASET2 on breast 
cancer cells cultured in 2D culture conditions, we decided to turn our attention to a more 
physiological 3D experimental model. 




Thus, as a preliminary assay for 3D culture, some of the previously selected MCF7 clones were 
also tested for their ability to form mammosphere in culture. The mammosphere assay originally 
developed by Dontu et al. [39] represents a well-established in vitro culture system commonly 
used for propagating healthy human mammary epithelial stem cells, based on the assumption 
that only undifferentiated cells will be able to survive and proliferate in suspension culture. The 
ability to form such structures is therefore related to the self-renewal ability.  
Of note, it is now widely accepted that most advanced tumors contain a sub-population of cells 
with stem cell properties that are considered responsible for the onset and progression of tumors 
[40]. In fact, cancer stem cells (CSCs) are uniquely able to reestablish the tumor when 
transplanted into xenograft models, they exhibit enhanced resistance to therapy and they can 
drive tumor recurrence and metastasis [40]. For all these reasons, CSCs represent critical 
therapeutic targets [41].  
In light of the previously reported pleiotropic roles of RNASET2 in tumor suppression, we 
reasoned that mammosphere growth assays could be used to determine whether RNASET2 can 
affect the number or growth pattern of mammosphere and/or on the expression of stem cell 
markers in the cells forming these structures. 
We therefore evaluated the mammosphere-forming ability of RNASET2-overespressing MCF7 
clones compared to control clones (MCF7 cells transfected with pcDNA3 empty vector).  
Interestingly, as shown in Figure 38 (upper panel), control clones formed a higher number of 
mammosphere compared to RNASET2-expressing clones, allowing us to hypothesize that 
RNASET2 might inhibit stem cell properties. Of note, this result was observed when considering 
two different size of mammosphere (50 or 100 µm). 
To further define the effects of RNASET2 on CSCs, we analyzed the expression pattern on known 
markers of stemness in this experimental system. Breast CSCs are generally identified as CD24-
/low/CD44+ cells and also display high expression of ALDH1.  
Two independent realtime qPCR expression assays were carried out in our model system for 
different epithelial and stemness markers. Significantly, clones overexpressing RNASET2 showed 




RNASET2 could be involved a signaling pathway controlling the cellular differentiation state 
(Figure 38 – lower panel). 
 
Figure 38. Difference in mammosphere-forming ability between MCF7 RNASET2-overexpressing clones 
and control clones and gene expression analysis 
(A) Three clones overexpressing RNASET2 were compared to control clones for their efficiency in forming 
mammospheres and the first ones showed a decrease in the number of these structures. Every sample 
was seeded in quadruplicates; results are shown as mean ± SEM. (B) The histograms show the mean for 
each of the experimental group of the same experiment. Statistical analysis was performed using one-
tailed Student’s t-test. *p<0.05. (C) Total RNA was isolated from three (left panel) or six (right panel) MCF7 
control/RNASET2-overexpressing clones, reverse transcribed and a qRT-PCR was carried out to analyze 
the expression of 5 different markers, with GAPDH as an internal standard. The fold change in gene 
expression was calculated using the 2- CT method and considering the mean of control clones with a level 
of expression equal to one. 
 
RNASET2 EXPRESSION IN HUMAN MAMMARY GLAND CELL POPULATIONS  
To further analyze the role of human RNASET2 in the mammary gland physiology, we analyzed 
its expression levels in different populations of healthy mammary gland tissue. 
Strikingly, when four different cell populations belonging to the healthy mammary gland (namely, 
luminal terminally differentiated cells, myoepithelial basal-like cells, stem cells and cells 
undergoing Epithelial-Mesenchymal Transition - EMT cells) were sorted by cytofluorimetry and 
subsequently analyzed for gene expression, the RNASET2 gene showed a cell type-dependent 
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(which represents the more differentiated one) and, conversely, a lower expression level in the 
stem cell and EMT populations (figures 39a and 39b).  
 
Figure 39. RNASET2 role in normal breast morphogenesis 
(A) Cells derived from mammary gland tissue were sorted by lineage markers and a microarray analysis 
was performed. (B) RNASET2 has a higher expression in the more differentiated population, the luminal 
cells.  
 
These results suggest a putative role for RNASET2 in stemness control in the mammary gland. Of 
note, our preliminary analysis on relapse-free survival data (figure 32) indicated that high 
RNASET2 expression levels were associated with a higher survival in luminal-A breast cancer 
patients. 
To better address this issue, luminal cells derived from normal breast samples were transduced 
with a lentiviral system in which a short hairpin RNA (shRNA) for RNASET2 gene silencing was 
constitutively expressed with the GFP as reporter gene.  
 
When these cells were cultured under conditions that promote 3D organoid formation, 
downregulation of RNASET2 resulted in a significantly altered morphogenetic pattern leading to 
abnormal 3D structures formation, whose main feature was a loose dissociated morphology 
(figure 40b). Indeed, these structures were not comparable with the development of branching 
tubules and cauliflower-like structures reminiscent of multi-branched lobular clusters that were 
A. luminal terminally differentiate (K18+, CDH1+)
B. basal-like myoepithelial (CD10+, EPCAM low,  
K14+) 
C. stem cells



































instead observed by culturing scrambles shRNA-expressing control luminal cells in 3D (figure 
40a). 
 
Figure 40: RNASET2 role in mammary organoid morphogenesis from donor sample BR20-11 
(A) 3D organoids structures from cells transduced with control vector. (B) 3D disordered structures from 
cells transduced with a vector for silencing RNASET2 expression. 
 
The proper downregulation of the RNASET2 gene in the luminal cell population was verified by 
real-time qPCR analysis, which confirmed a dramatic reduction of this gene’s expression in the 
luminal cell population derived from sample BR20-11 (figure 41). 
 
Figure 41: Evaluation of RNASET2 expression in mammary organoids generated from samples BR20-11 
and BR22 following shRNA-mediated downregulation of RNASET2 
Quantitative PCR analysis was carried out in scrambled (“RNASET2 UP”) vs. RNASET2 shRNAs-expressing 








To define putative RNASET2-driven molecular alterations associated with the observed structural 
disruption of the organoids, the latter were analyzed by immunofluorescence assays. In keeping 
with the notion that RNASET2-silenced 3D structures were not representative of normal 3D 
mammary organoids, epithelial cell-to-cell contacts were found to be significantly disrupted in 
these structures (data not shown). Moreover, a significant remodeling on the actin cytoskeleton, 
coupled to a marked downregulation of proteins associated with the differentiated state of 
luminal cells (cytokeratins K14 and K18) was observed in RNASET2-silenced structures compared 
to control organoids. (figure 42). 
 
Figure 42: Immunofluorescence assays on mammary organoids 
Cells derived from mammary gland tissue and transduced with control vector or SH RNASET2 vector were 
analysed for the actin cytoskeleton pattern and the expression of two cytokeratins marker (K14 and K18). 
 
 
The loss of normal 3D organization in the mammary parenchyma represents one of the hallmarks 
of breast tumor’s morphology and is characterized by the appearance of de-differentiated (due 
to loss of epithelial cell morphology) and invasive-like parenchyma luminal cells. In agreement, 
downregulation of RNASET2 in the 3D structures was associated with a decrease in beta-catenin 
epithelial marker expression (figure 43), coupled to an increase in expression of the canonical 






















Figure 43: Immunofluorescence assays on mammary organoids cryosections 
Analysis by immunofluorescence of the beta-catenin epithelial marker. SH RNASET2 cells unable to form 
an ordered 3D structure show a marked downregulation of this protein. 
 
By repeating the experiment to analyze samples at different time points (7 or 14 days), we 
discovered that RNASET2 silencing prevented the proper development of the organoid (figure 
44, compare upper and lower pictures). Indeed, as shown in figure 44, control cells are able to 
develop a proper structure with a clear actin cytoskeleton pattern, whereas RNASET2-silenced 
cells eventually die, cells contacts are lost and actin fibers are disrupted. 
Of note, since lentiviral transduction efficiency was probably lower than 100%, the luminal cell 
population was likely composed of both infected, RNASET2-silenced and uninfected RNASET2-
expressing cells at the beginning of the experiment. Indeed, the percentage of GFP-positive cells 
in control organoids at 7 days was ranging from 10 to 50% (figure 44, upper panel). 
In this regard, it is worth noting that during organoid formation GFP+/RNASET2- cells were 
apparently lost with time, as demonstrated by the very low number of GFP+/RNASET2- cells at 
day 7 following organoid culture, coupled to the concomitant occurrence of GFP-/RNASET2+ cells 
(figure 44, right lower panel). Significantly, GFP+/RNASET2- cells were completely missing at 14 
days. 
We therefore reckon that, in the first days of 3D culturing of luminal cells, the likely 


















the few RNASET2-expressing cells present at early stages are not able to compensate for the lack 
of this protein in most cells, which impairs organoid formation.  
We therefore hypothesize that the lack of RNASET2 in luminal cells, which initially outnumber 
other cells, is a key factor in the first steps for the organoid formation process.  
 
 
Figure 44: Immunofluorescence assays on mammary organoids cryosections 
Analysis by immunofluorescence of actin cytoskeleton (Phalloidin) and RNASET2 expression. SH RNASET2 
cells unable to form an ordered 3D structure are lost over time and no actin fibers material is visible 
already at 7 days. 
 
 
Taken together, the above described data, obtained in several independent experimental 
breast cancer models, are of key relevance. In fact, whereas on one hand they provide an 
independent support to the notion of the RNASET2 gene as a tumor suppressor acting on a wide 
spectrum of human cancers, on the other hand they shed new light to an unprecedented 
potential mechanism by which this highly pleiotropic gene carries out its anti-tumoral activity, 
i.e. by controlling the differentiation state of  mammary epithelial cells, which in turn is tightly 


































Ribonucleases represent a very ancient class of enzymes, whose role in degrading or 
processing RNA molecules has been exploited by nature to carry out an impressive range of 
biological functions. Indeed, the key role assigned to RNases in living organisms is testified 
beyond any reasonable doubt by the impressive number of RNase-encoding genes that have 
been discovered in many species, particularly in higher eukaryotes. For instance, the human 
genome is known to encode at least thirteen members just for the vertebrate-restricted RNAse 
A superfamily [42], the most widely investigated so far. However, several ribonuclease genes 
belonging to other subfamilies have been reported as well in higher organisms in the last 
decades.  
Of note, notwithstanding the disparate biological processes regulated by this large class 
of enzymes, a common theme which has soon emerged from the functional analysis of several 
RNases is their role in host defense. In this context, a key role in displaying anti-viral and anti-
bacterial activities has been reported for an impressive number of ribonucleases. Of note, such 
host defense role, which most often relies on the catalytic activity of these enzymes, entails a 
strong cytotoxic activity, which in turn has attracted a growing attention in order to exploit 
ribonucleases as potential anticancer molecules [43]. Moreover, one relevant biological process 
by which several ribonucleases are engaged in host defense is immune modulation, in particular 
for those RNases that are secreted in the extracellular space [12]. For instance, an impressive 
number of human RNAses belonging to the A superfamily are known to be secreted by several 
cell types in order to carry out a range of activities involved in host defense, inflammation and 
tissue remodeling by means of immune modulation [22]. 
More recently, the role in cancer growth control coupled to immune modulation has been 
extended to some members of the Rh/T2/S family of extracellular ribonucleases, the most 
ancient and evolutionary conserved [22]. The ubiquitous distribution of these enzymes among 
taxa, coupled to the fact that, unlike RNase A members, T2 ribonucleases often carry out their 
biological functions independently from their catalytic activity, suggest that these enzymes 
represent highly pleiotropic molecules involved in very ancient biological processes. 
Unlike RNase A family members, the human genome is known to encode a single gene 




behave as a powerful tumor suppressor. In particular, in recent years we reported that RNASET2 
overexpression in human ovarian cancer cells is associated with a strong suppression of their 
tumorigenicity in vivo [16]. Noteworthy, the observed control of tumor growth apparently relied 
on the establishment of a cross-talk between RNASET2-overexpressing cancer cells and the 
tumor microenvironment, with the monocyte/macrophage cell lineage representing the most 
likely target of RNASET2 activity [19].  
Interestingly, our first experimental data, reported with the Hey3Met2 cell line, seemed 
to suggest an asymmetric tumor-suppressive activity for RNASET2, which was apparently carried 
out in vivo but not in vitro [19]. These biological properties led us to rank RNASET2 as a novel 
member of the growing family of "tumor antagonizing/malignancy suppressor genes" [44], 
whose main feature is their ability to carry out a non-cell autonomous, microenvironment-
mediated control of tumorigenesis [45]. Of note, the catalytic activity of RNASET2 turned out to 
be dispensable for its oncosuppressive role [16]. 
With further investigations in other ovarian cancer cell line model, however, independent 
cell-autonomous oncosuppressive roles were attributed to this gene as well, which might further 
enhance its tumor suppressive activity. In particular, RNASET2 was reported to behave as a stress 
response gene endowed with a marked effect on the actin cytoskeleton organization and with 
the ability to affect several cancer-related parameters in vitro [24]. Moreover, the tumor 
suppressive role of RNASET2 has been reported for other human cancer types in recent years, 
such as colorectal cancer and malignant melanoma [17]. 
Altogether, the experimental data gathered on different human cancer models thus 
suggest a highly pleiotropic role for RNASET2 in tumor suppression, whereby different cellular 
parameters related to cancer growth are affected by changes in the expression levels on this 
protein, but a marked perturbation of the cancer microenvironment is also carried out by this 
gene at the same time. 
 
Within this frame, the general aim of my Ph.D work was to further characterize the 





As mentioned above, since T2 RNases represent the most ancient and evolutionarily 
widespread ribonuclease family, they probably share some very ancient and critical functions. 
One of these biological properties is likely the modulation of the innate immune system. Indeed, 
the T2 ribonuclease orthologous gene encoded by the trematode Schistosoma mansonii encodes 
for a protein (Omega-1) that has been reported to prime the host’s dendritic cell toward a Th2-
polarized response [20]. Moreover, a role for RNASET2 in the activation of the innate immune 
system in the invertebrate model Hirudo medicinalis has also recently described in our lab [46] 
and at least two other members of the T2 ribonuclease protein family have been reported to 
modulate the mammalian innate immune system [20,47]. 
These experimental evidences, coupled to our previous in vivo experiments and 
immunohistochemistry analysis on human ovarian cancer cell-derived xenograft tumours, 
prompted us to investigate a potential effect of RNASET2 on macrophage polarization pattern in 
vitro. 
Using the human promyelocytic THP-1 cell line, a widely used and established cellular model of 
macrophage differentiation and polarization, we found that, following the silencing of 
endogenous RNASET2 expression in these cells, a marked effect on their polarization pattern was 
observed, consisting in both a dramatic reinforcement of the M2 polarization pattern upon IL-4 
stimulation, coupled with a moderately weakened M1 response under IFN /LPS stimulation were 
observed in these cells. 
This was the first evidence supporting a role for RNASET2 in the regulation of 
macrophages polarization pattern in vitro, and these data lead us to further wonder if exogenous 
administration of RNASET2 protein could mimic the effect observed by experimentally 
manipulating the endogenous protein expression levels.  
Of note, injection of human recombinant RNASET2 in Hirudo medicinalis was recently 
shown by our group to induce both a massive migration of cells belonging to the macrophages 
lineage to the injection site and an increase in the expression level of the endogenous T2 RNase 
protein in the same innate immune cells [46].  
A rescue assay in RNASET2-silenced THP-1 cells was therefore carried out using 




RNASET2-silenced THP-1 cells with recombinant RNASET2 could rescue the polarization pattern 
seen in parental THP-1 cells, although the observed reversion of the polarized phenotype was 
only partial. We reckon that such partial effect might be attributable to the expression system 
used to produce the recombinant protein. Indeed, a recent work on the T2 Rnase Omega-1 from 
Schistosoma mansonii reported a key role for the mannose-receptor in Omega-1 uptake by 
mammalian dendritic cells [48], which is required for Th-2 polarization of these cells. Since the 
glycosylation pattern of proteins produced in P. pastoris is known to substantially differ from that 
observed in mammalian cells (specifically concerning mannose residues), should the mannose 
receptor be involved in human RNASET2 binding by macrophages as well, the Pichia pastoris-
derived recombinant RNASET2 protein might not have completely rescued the polarization 
phenotype of THP-1 cells due do some critical differences in its glycosylation pattern when 
compared to the human endogenous protein that was silenced by RNA interference. 
To address this issue, the production of human recombinant RNASET2 in mammalian CHO cells 
is undergoing in our lab. 
Of note, since the mannose receptor has long been described as an M2-specific 
macrophage marker, the report from the Omega-1 binding pattern suggests that the human 
target cells for RNASET2-mediated polarization might be represented by M2 macrophages 
themselves. Under this scenario, RNASET2 might operate by promoting an M2 to M1 shift in vivo, 
which in turn might trigger a transition from a pro- to an anti-tumoral microenvironment. 
 Therefore, one task of key relevance for our future investigations will be to assess the 
role of the mannose receptor in RNASET2-mediated macrophage polarization, by means of RNAi 
assays coupled to the use of specific agonists of the mannose receptor. 
To further validate the results obtained in the THP-1 experimental model, we started a 
preliminary polarization assay using PBMC-derived human monocytes as a target cell population. 
The result form our first attempts were quite disappointing, since the macrophage 
polarization regimen applied was only partially effective, thus precluding a reliable evaluation of 
the RNASET2 role in these cells. Moreover, the problem of donor-to-donor variability, which has 
long been recognized in experiments using PBMC-derived cells, has probably confounded the 




However, even in this imperfect experimental system we were able to observe a trend for 
an RNASET2-mediated effect on these cell’s polarization pattern. Therefore, further efforts are 
ongoing in our lab in order to both improve the polarization protocol for PBMC-derived  
monocytes (particularly for M1 macrophages) and at the same time change our experimental 
plan by pooling PBMC-derived monocytes from multiple independent donors rather than using 
single-donors-derived independent cell populations.  
Moreover, in order to get a more comprehensive picture of the role played by RNASET2 in 
macrophage polarization, we plan to significantly increase the number of polarization markers to 
be analyzed in both THP-1 and PBMC-derived-monocytes, by using customized qPCR arrays 
including more than one hundred genes involved in innate immunity. 
Human cancer cell lines whose RNASET2 expression level has been experimentally 
manipulated will also be co-cultured with both THP-1 and PBMC-derived macrophages, in order 
to reproduce in vitro and better investigate the role of macrophages in RNASET2-mediated tumor 
suppression. 
Finally, several collaborations with medical oncology research labs have been recently 
launched by our group in order to start a detailed survey of a panel of human cancer types, aimed 
at both evaluating the correlation of RNASET2 expression with tumor grade or stage and the 
putative involvement of stromal macrophage infiltrates. 
 
Taken together, the experimental data presented in this first part of my PhD work are in 
keeping with our previously reported in vivo xenograft-based data, where RNASET2 
overexpression and secretion by cancer cells resulted in the suppression of their tumorigenic 
potential, coupled to a massive recruitment of M1-polarized macrophages in the tumour mass, 
likely polarized by RNASET2 at the expense of M2 macrophages.  
Of note, RNASET2 has been recently described as a stress-response protein, whose 
expression and secretion is markedly increased following induction of a wide range of cellular 
stresses [24]. Among these are included oxidative stress and hypoxia, which represent two stress 
conditions typically experienced by cancer cells. On the basis of this observations, RNASET2 has 




to alert microenvironmental components (such as cells of the innate immune system) of the 
occurrence of a pre-neoplastic state in order to mount a proper host defense response. 
In this context, it is worth noting that several current therapeutic approaches in cancer 
research are focused on reprogramming the immune cell populations within the tumor 
microenvironment towards an anti-cancer response. For instance, one largely explored strategy 
entails Tumor-Associated Macrophages (TAMs) reprogramming towards an M1-polarized, anti-
tumor role [49]. Thus, our results potentially suggest a translational application of RNASET2 as a 
powerful tool in this area of anti-cancer research.  
 
In light of the experimental evidences supporting a role of the immune system in 
RNASET2-mediated tumor suppression, to further address the potential therapeutic applications 
of this protein we next asked whether the tumor suppressive role observed for RNASET2 in 
xenograft-based assays carried out in immunocompromised experimental models could be 
confirmed in the context of a perfectly efficient immune system. We therefore sought to develop 
a syngeneic murine model to get further insights into the non cell-autonomous tumor 
suppressive role of RNASET2 in vivo. This model could provide us with key information on the 
interplay of RNASET2 with the tumor microenvironment in a more physiologic context and 
therefore allow us to perform a deeper investigation on the extent of the RNASET2-mediated 
cross-talk between cancer cells and immune cells.  
One of my PhD work’s aims was therefore to define a suitable experimental model 
consisting of a mouse cell line for manipulating RNASET2 expression and producing cell clones to 
be subsequently used in in vivo experiments.  
Several cell lines representative of a range of murine cancers were chosen to this aim and their 
endogenous RNASET2 expression levels was first analyzed at both the transcript and protein 
level. Since we observed a very low endogenous expression of mouse Rnaset2 in all murine cell 
lines, we choose a gene over-expression approach for our purposes. 
To this end, we set up transient transfection assays in at least three different cell lines with 




Quite unexpectedly, in all cell lines tested only the human protein was effectively over-
expressed, while the murine protein was either expressed at very low levels or undetectable.  
Since a protein alignment approach revealed some potentially relevant differences 
between the human and mouse RNASET2 proteins, we speculated that the observed data might 
be attributable to some potentially toxic or anti-proliferative activity of the murine protein with 
respect to its human counterpart. To address this issue, we turned to the development of an 
inducible expression system.  
Unfortunately, we were once again unable to get the murine protein expressed following 
doxycycline-induced expression in any of the cell lines tested, although we could demonstrate 
that the murine transgene was properly induced at the RNA level.  
These data provided further support to the notion that the mouse Rnaset2 protein is 
somehow incompatible with cell viability and/or proliferation. In this regard, it is worth noting 
that although our anti-RNASET2 antibody was raised against the human protein, it could easily 
detect murine Rnaset2 following western blot analysis on murine adult post-mitotic tissues. 
This observation seems to rule out any problem of antibody sensitivity as a possible 
reason for the lack of murine protein detection in our transfection assays, and at the same time 
points to an antiproliferative rather than cytotoxic effect of this protein. 
 
Drawing from these experimental results, we next decided to investigate whether some 
mouse protein portion could be responsible for the marked human vs. murine biological 
difference. To this end, we carried out a protein swap domain approach by assembling different 
constitutive expression vectors bearing the human and mouse full-length cDNA, a C-terminal 
deleted version of the mRnaset2 and two chimeric human-murine versions of RNASET2.  
At a first sight, transient transfection assays seemed to point to the N-terminal murine 
portion as the one responsible for the observed lack of protein expression, but when we turned 
to stable transfections in TS/A and C51 cell lines, both chimeric versions turned out to be 
expressed in cell pools, although at a very low level. Moreover, the mouse truncated version was 
expressed as well. On one hand, these data were disappointing since we could not 




its lack of expression. However, the observation of a weak expression signal from some murine 
expression vectors prompted us to make a large-scale effort in order to isolate stably transfected 
single clones expressing the murine protein. 
The achievement of this task turned out to be quite expensive and time-consuming, since 
a very high number of transfected clones had to be screened in order to obtain a few murine 
Rnaset2-expressing cell clones, in line with the previous difficulty experienced with pools of 
transfected clones. Of note, by comparing the expression levels in the few T2 RNase-expressing 
single clones, the mouse full-length Rnaset2 protein turned out to be always expressed less 
efficiently that the murine truncated version, which was in turn expressed at lower levels when 
compared to human full-length RNASET2. Thus, our results confirmed the occurrence of a kind 
of functional difference between the human and murine proteins, whose nature is still to be 
defined. 
Despite this difference, the successful isolation of a handful of murine Rnaset2-expressing 
clones paved the way for studies aimed at defining the functional features of this protein. We 
started to address this issue by analyzing the proliferation rate in vitro. Interestingly, the full 
length mRnaset2 protein displayed a marked antiproliferative ability in C51 cells, which was much 
more attenuated for cell expressing the truncated protein. The same trend was observed in TS/A 
cells, although the observed differences were not statistically significant. 
These data are in keeping with our hypothesis of an antiproliferative rather than toxic 
effect of murine RNASET2, since cell viability was apparently unaffected by mouse Rnaset2 
expression by visual inspection (data not shown). Moreover, the observed difference between 
the full-length and truncated versions of the protein pointed at the C-terminal portion of murine 
Rnaset2 as the likely determinant of a key functional property. 
Besides these in vitro studies, the availability of murine Rnaset2-expressing clones 
allowed us to start developing a syngeneic experimental model for further investigations. 
To this end, we used one clone for each experimental group from the C51 cell line to carry out a 
pilot experiment on immunocompetent Balb/c mice. Strikingly, we observed a marked 
suppression of the in vivo tumor growth rate in cells overexpressing the full length mRnaset2. Of 




similar to control clones, again pointing at some crucial functional element at the C-terminal end 
of the protein. 
To our knowledge, this is the first evidence supporting the in vivo oncosuppressive role of 
a T2 ribonuclease in a fully immunocompetent experimental model. In this context, this result 
paves the way for a new line of research, aimed at both defining the putative occurrence of a 
cross-talk between cancer-cell derived RNASET2 and the components of the adaptive immune 
system and at the same time to develop preclinical model aimed at investigating the potential of 
RNASET2 as a potentially useful agent in cancer therapy. 
Our laboratory will be particularly involved in the first task, whereby murine Rnaset2-expressing 
clones will be deeply investigated to assess a wide panel of cancer-related parameters in vitro 
assays and to compare them with those associated with human RNASET2 overexpression. 
At the same time, further in vivo studies will be carried out in order to achieve for the first time 
a thorough characterization of an immunocompetent tumor microenvironment in mouse 
Rnaset2-expressing tumors, by means of both IHC assays (to define the putative involvement of 
cellular component of the innate and adaptive immune system in Rnaset2-mediated tumor 
suppression) and functional in vitro co-culture experiments with Rnaset2-expressing cancer cells 
and several cellular component of the tumor microenvironment.  
 
Collectively, the experimental data presented in the first part of this PhD work provide a 
strong evidence in support of both a marked and evolutionary conserved activity of RNASET2 as 
a tumor suppressor and at the same time the role played by the immune system in RNASET2-
mediated tumor suppression.  
However, T2 ribonucleases are widely known as pleiotropic proteins involved in several 
biological processes [22]. For instance, in recent years several research groups (including ours) 
reported a cell-autonomous oncosuppressive role for several members of the T2 family 
[23,24,25]. According to the chosen experimental model and the human T2 Rnase under 
investigation, such cell-autonomous role entails a wide range of cancer-related biological 
processes, such as induction of apoptosis, remodeling of the cytoskeleton, prevention of 




observations, coupled to the broad spectrum of tumors associated with genetic alteration in the 
genomic region in which the RNASET2 gene maps, prompted us to confirm (and possibly extend) 
the current knowledge about the oncosuppressive roles of human RNASET2 in an independent 
cancer model. In this context, since one of the cancer types in which the 6q27 region is frequently 
deleted is breast cancer, we decided to investigate the putative involvement of RNASET2 in this 
cancer type. The human MCF7 cell line was chosen for this purpose, since it  represents a valuable 
model to investigate the role played by a gene of interest not only in 2D in vitro assays but also 
in three-dimensional cultures, due to its ability to grow in suspension under proper culture 
conditions to form 3D structures (called mammospheres) that better reproduce the architectural 
features of the human mammary gland in vitro, thus providing a more physiological experimental 
system [32;50-53]. 
A preliminary analysis of the RNASET2 expression level in this cell line showed that MCF7 
cells has low levels of endogenous expression compared to other cell lines previously used in our 
laboratory. These findings prompted us to generate human RNASET2-overexpressing MCF7 
clones for further investigations. A panel of such clones were therefore generated and few of 
them were selected for preliminary functional assays. 
We first evaluated the effect of RNASET2 overexpression on some cancer-related parameters and 
observed a slight variability on cell proliferation rate between RNASET2-overexpressing clones 
and control clones. By contrast, a colony-formation assay showed that control clones produced 
a significant greater number of colonies with respect to RNASET2-overexpressing clones. Since 
colony formation is an in vitro cell survival assay that tests the ability of single cells to undergo 
“unlimited” proliferation, the results are in keeping with the notion of a cell-autonomous tumor 
suppressive role of RNASET2 in an experimental model different from ovarian cancer. 
Furthermore, since apoptosis represents a biological process deeply involved in cancer 
development and progression, we decided to assess whether RNASET2 could affect this biological 
process as well in MCF7 cells, both at basal condition and following apoptogenic treatment. 
Again, we found a clear effect of RNASET2 on this parameter, since clones overexpressing wild-




with CoCl2 or cis-platinum) with respect to control clones. This result is once again in keeping 
with our previous data in the ovarian cancer model. 
A similar conclusion could be drawn by turning our attention to RNASET2’s effects on the 
cell cytoskeleton. Malignant cancer cells utilize their intrinsic migratory ability to invade adjacent 
tissues and cytoskeletal rearrangements are known to be of paramount importance in this 
process. In agreement with our previous data in ovarian cancer models, a distinct RNASET2-
mediated re-organization of the cell cytoskeleton was observed in MCF7 cells as well, since the 
actin structural network was consistently rearranged to a complex network with several long 
actin-filament bundles crossing the cell length following RNASET2 overexpression.  
The observed cytoskeletal dynamics was in keeping not only with our previous data on an 
ovarian cancer-derived experimental model, but also with the previously reported role of 
Schistosoma mansoni Omega-1 protein in cytoskeleton rearrangements [20;24], demonstrating 
once again the evolutionary conservations of a biological process mediated by T2 ribonucleases. 
Taken together, the results from these in vitro assays lend further credit to the notion of a 
strong cell-autonomous oncosuppressive role for RNASET2 in a human breast cancer cell model. 
If the previously reported data from human malignant melanoma are also taken into account 
[17], the emerging picture points at RNASET2 as an oncosuppressor gene endowed with a 
common role in most cancer types showing chromosomal rearrangements in the 6q27 region 
that have been investigated so far.  
However, the well-established pleiotropic roles assigned to T2 ribonucleases, coupled to the 
intrinsic complexity of the tumorigenic process, suggest a putative scenario by which RNASET2 
might act as a tumor suppressor in different ways for different cancer types. Of note, the MCF7 
cell model is particularly attractive to address this issue, due to the previously mentioned ability 
of this cell line to grow in both 2D and 3D culture condition. The latter feature is of key relevance 
in this regard, since it allows to address a critical issue related to cancer growth, which is the role 
of cell differentiation and tumor heterogeneity. 
Intra-tumor heterogeneity represents a well-documented feature of cancer and posits great 
challenge to the successful development of antineoplastic therapies. Indeed, it is now widely 




are considered responsible for the onset and progression of tumors. Of note, cancer stem cells 
(CSCs) are uniquely able to reform the tumor when transplanted into xenograft models, exhibit 
enhanced resistance to therapy and can drive tumor recurrence and metastasis. For all these 
reasons CSCs represent key current therapeutic targets [41]. We therefore decided to exploit the 
experimental versatility of the MCF7 cell model to further investigate the putative effect of 
RNASET2 in breast cancer development, with a particular attention to its putative role in CSCs 
biology.  
To this end, we decided to take advantage of the mammosphere assay [39], a 3D in vitro 
culture system commonly used for propagating human mammary epithelial stem cells and based 
on the assumption that only undifferentiated cells such as CSCs will be able to survive and 
proliferate in suspension culture. The ability to form such structures is therefore related to self-
renewal ability.  
We therefore carried out this assay to determine the ability of RNASET2 to affect both 
mammospheres formation and/or the expression level of stem cell markers in the cells forming 
these 3D structures, under the assumption that breast CSCs are generally identified as a CD24-
/low/CD44+ population and have high expression of ALDH1 [54].  
Strikingly, our experimental data supported the hypothesis that RNASET2 could be involved in 
the regulation of MCF7 differentiated state. In fact, a clear negative correlation was found 
between RNASET2 expression and the number of mammospheres formed. Additionally, 
mammospheres derived from RNASET2-overexpressing clones showed a higher expression of 
CD24 and a lower expression of ALDH1, supporting the hypothesis of a role for RNASET2 in breast 
cell differentiation. 
Recent data gathered on a collaborative basis with our group further support this hypothesis. 
In fact, to get a deeper insight into the role of human RNASET2 in the mammary gland, we 
proceeded to analyse its expression levels in different populations of the healthy mammary 
gland. Strikingly, the RNASET2 gene showed the highest expression levels in the more 
differentiated breast cell population (i.e. the luminal one) whereas less differentiated cells (such 




To better investigate this issue, we evaluated the effect of RNASET2 downregulation in 
human organoids generated from healthy breast luminal cells.  
Of note, silencing RNASET2 expression in the luminal population resulted in the formation of 
abnormal 3D structures with a concomitant decrease on the expression of some epithelial 
markers. 
Though preliminary, we reckon that these data are of key relevance since they further 
support the extensive pleiotropy of the RNASET2 gene by unveiling a previously unknown 
mechanism by which this gene act to suppress tumor growth. In particular, the apparent role of 
RNASET2 in controlling the cell differentiation state in MCF7 cells might be put in relation with 
the previously established ability of the RNASET2 protein to affect the actin cytoskeleton [24]. 
Indeed, the cell polarization pattern of epithelial cells (which is in part controlled by 
specific cytoskeletal organization patterns) has long been recognized to control their 
differentiation pattern. Therefore, the previously reported ability of T2 ribonucleases to affect 
the actin cytoskeleton might provide a functional link to explain the ability to control the cell 
differentiation pattern that we observed in the MCF7 experimental model. 
 
Although many details still need to be further investigated to draw a comprehensive 
picture on the molecular and cellular mechanisms underlying  RNASET2-mediated tumor 
suppression, our results laid the bases for future studies aiming at dissecting, at the widest 
possible range, the involvement of RNASET2 in tumor suppression by means of several 
mechanisms, such as innate immune cells recruitment and polarization, cell-autonomous 
antiproliferative and pro-apoptotic activity, and cell cytoskeleton remodeling, which might in 
turn endow T2 RNases with the ability to control the cell differentiation state. 
All these disparate functional features of the RNASET2 gene are going to be addressed in 
our laboratory in the near future, by exploiting the above-mentioned experimental models in 
order to shed more light on the molecular and cellular effectors involved in the several biological 
processes in which this very ancient and highly pleiotropic gene is involved. 
As long as our breast cancer model is concerned, we plan to carry out a detailed survey 




organoids. At the same time, a zebrafish-based model is going to be developed on a collaborative 
basis in order to investigate the role of RNASET2 in cell differentiation and organ morphogenesis 
in a well-established and easily available animal model. 
On the long-term, we reckon that these investigations might be exploited in medical 
translation approaches aimed at exploiting the RNASET2 protein in anticancer therapy. Indeed, 
ribonucleases have already been considered as potential anticancer drugs and some RNase A 
family members have already proven to represent promising therapeutic tools for cancer 
treatment [55,56].  
For example, Onconase, an amphibian ribonuclease belonging to the RNase A family, has been 
included in clinical trials for the treatment of mesothelioma, a rare tumor with no effective 
treatments to date. We reckon that human RNASET2 might soon be included in the list of 
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